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Abstract	  
Exploiting	  oxidative	   stress	  has	   recently	  emerged	  as	  a	  plausible	   strategy	   for	   treatment	  of	  human	  
Cancer	   and	   anti-­‐oxidant	   defences	   are	   implicated	   in	   resistance	   to	   chemo-­‐	   and	   radiotherapy.	  	  
Targeted	  suppression	  of	  anti-­‐oxidant	  defences	  could	  thus	  broadly	  improve	  therapeutic	  outcomes.	  	  
Here	  we	   identify	  the	  AMPK-­‐related	  kinase	  NUAK1	  as	  a	  key	  component	  of	  the	  anti-­‐oxidant	  stress	  
response	  pathway	  and	  reveal	  a	  specific	   requirement	   for	   this	   role	  of	  NUAK1	   in	  colorectal	  cancer.	  	  
We	   show	   that	   NUAK1	   is	   activated	   by	   oxidative	   stress	   and	   that	   this	   activation	   is	   required	   to	  
facilitate	   nuclear	   import	   of	   the	   anti-­‐oxidant	   master	   regulator	   NRF2:	   Activation	   of	   NUAK1	  
coordinates	  PP1β	  inhibition	  with	  AKT	  activation	  in	  order	  to	  suppress	  GSK3β-­‐dependent	  inhibition	  
of	   NRF2	   nuclear	   import.	   	   Deletion	   of	   NUAK1	   suppresses	   formation	   of	   colorectal	   tumors,	   while	  
acute	  depletion	  of	  NUAK1	  induces	  regression	  of	  pre-­‐existing	  autochthonous	  tumors.	  	  Importantly,	  
elevated	   expression	   of	   NUAK1	   in	   human	   colorectal	   cancer	   is	   associated	   with	   more	   aggressive	  
disease	  and	  reduced	  overall	  survival.	  
	  
Significance	  
This	   work	   identifies	   NUAK1	   as	   a	   key	   facilitator	   of	   the	   adaptive	   anti-­‐oxidant	   response	   that	   is	  
associated	   with	   aggressive	   disease	   and	   worse	   outcome	   in	   human	   CRC.	   	   Our	   data	   suggest	   that	  
transient	  NUAK1	  inhibition	  may	  provide	  a	  safe	  and	  effective	  means	  for	  treatment	  of	  human	  CRC	  




NUAK1;	  ARK5;	  NRF2;	  Oxidative	  stress;	  Metabolic	  stress;	  Colorectal	  Cancer;	  Cancer	  Therapy	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Introduction	  
The	   relentless	   drive	   to	   proliferate	   exposes	   tumor	   cells	   to	   considerable	   metabolic	   stress.	  
Proliferating	   tumor	   cells	   increase	   nutrient	   consumption	   in	   order	   to	   balance	   the	   competing	  
demands	  of	  macromolecular	  synthesis,	  towards	  which	  a	  large	  proportion	  of	  nutrient	  metabolites	  
are	   diverted,	   with	   the	   energetic	   cost	   of	   sustaining	   viability,	   measured	   in	   ATP	   (1).	   Increased	  
metabolic	   activity	   elevates	   production	   of	   reactive	   oxygen	   species	   (ROS),	   altering	   signal	  
transduction	  and,	  at	  very	  high	  levels,	  inflicting	  damage	  upon	  lipids,	  proteins	  and	  nucleic	  acids	  (2).	  
In	   the	   context	   of	   a	   growing	   solid	   tumor	  with	   ineffective	   vascularity,	   tumor	   cells	   are	   commonly	  
deprived	   of	   their	   preferred	   nutrients	   and	   exposed	   to	   hypoxia,	   which	   also	   increases	   ROS	  
production,	   adding	   cell-­‐extrinsic	   sources	   of	   further	   metabolic	   stress.	   In	   order	   to	   survive	   such	  
stress,	   tumor	   cells	   must	   adapt	   flexibly	   and	   continuously	   by	   modulating	   their	   rates	   of	  
macromolecular	   synthesis,	   cell	   growth,	   and	  proliferation,	   in	   order	   to	  maintain	  ATP	  homeostasis	  
and	  counteract	  ROS.	  Failure	  to	  do	  so	  leads	  to	  ATP	  collapse,	  toxic	  levels	  of	  ROS,	  and	  loss	  of	  viability.	  	  
As	  such,	  targeted	  suppression	  of	  adaptive	  measures	  used	  by	  tumor	  cells	  to	  counteract	  metabolic	  
stress	  may	  yield	  therapeutic	  benefit	  in	  cancer	  treatment.	  	  	  
NUAK1	   (aka	  ARK5)	   is	  one	  of	  12	  kinases	   related	  by	  sequence	  homology	   to	   the	  catalytic	  α	  
subunits	  of	  AMPK	  (3).	  Collectively,	  these	  kinase	  play	  various	  roles	  in	  regulating	  cell	  adhesion	  and	  
polarity,	   cellular	   and	   organismal	   metabolism,	   and	   in	   the	   cellular	   response	   to	   various	   forms	   of	  
stress,	   including	   oxidative,	   osmotic	   and	   energetic	   stress	   (4,	   5).	   NUAK1	   is	   a	   common	   target	   of	  
several	  miRNAs	  that	  are	  frequently	  suppressed	  in	  cancer,	  suggesting	  a	  potential	  role	  for	  NUAK1	  in	  
tumorigenesis	   (6-­‐8).	   Accordingly,	   we	   previously	   reported	   that	   NUAK1	   is	   required	   to	   sustain	  
viability	  of	  cancer	  cells	  when	  MYC	  is	  overexpressed	  (9).	  	  
	   In	   contrast	   with	   the	   widely	   studied	   AMPK,	   the	   molecular	   targets	   and	   downstream	  
pathways	   governed	   by	   NUAK1	   are	   poorly	   defined.	   To	   date,	   the	   best-­‐characterized	   substrate	   of	  
NUAK1	   is	   the	   PP1β	   subunit,	   MYPT1	   (PPP1R12A).	   During	   cell	   detachment,	   phosphorylation	   of	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MYPT1	   by	   NUAK1	   inhibits	   PP1β	   phosphatase	   activity	   towards	   myosin	   light	   chain.	   Inhibition	   of	  
NUAK1	  thus	  increases	  PP1β	  activity,	  delaying	  cell	  detachment	  and	  suppressing	  cell	  migration	  (10).	  
Other	  work	  points	  to	  a	  role	  for	  NUAK1	  in	  metabolic	  regulation.	  Muscle-­‐specific	  deletion	  of	  Nuak1	  
protects	  mice	   from	  high	   fat	  diet-­‐induced	  diabetes,	  attributable	   to	   increased	  glucose	  uptake	  and	  
increased	   conversion	   of	   glucose	   to	   glycogen	   by	  Nuak1-­‐deficient	   skeletal	  muscle	   (11).	   An	   earlier	  
study	  showed	  that	  NUAK1	  protects	  cancer	  cells	  from	  nutrient	  deprivation-­‐induced	  apoptosis	  (12).	  
In	   the	   context	   of	   MYC	   overexpression,	   we	   showed	   that	   NUAK1	   is	   required	   to	   maintain	   ATP	  
homeostasis,	   in	  part	  by	   facilitating	  AMPK-­‐dependent	   inhibition	  of	  TORC1-­‐driven	  macromolecular	  
synthesis	   (9,	   13).	   Failure	   to	   engage	   this	   checkpoint	   results	   in	   cell	   death	   under	   conditions	   of	  
metabolic	  stress	  (14-­‐16).	  
	   Our	   previous	   work	   thus	   suggested	   that	   NUAK1	  may	   present	   a	   good	   target	   for	   therapy,	  
specifically	   in	   the	   context	   of	   MYC-­‐driven	   cancers.	   Human	   colorectal	   cancer	   (CRC)	   is	   uniformly	  
characterized	  by	  deregulated	  expression	  of	  MYC	  and	  mouse	  models	  have	  shown	  that	  expression	  
of	  endogenous	  Myc	  is	  required	  for	  intestinal	  polyp	  formation	  upon	  loss	  of	  Apc,	  the	  most	  common	  
tumor-­‐initiating	  event	  in	  human	  CRC	  (17,	  18).	  We	  asked	  therefore	  if	  NUAK1	  is	  required	  to	  support	  
tumor	   cell	   viability	   in	  CRC.	  Here	  we	   show	   that	  NUAK1	   is	   overexpressed	   in	  human	  CRC	  and	   that	  
high	   NUAK1	   expression	   correlates	   with	   reduced	   overall	   survival.	   Using	   genetically	   engineered	  
mouse	  models	  of	  CRC	  driven	  by	  sporadic	   loss	  of	  Apc,	  we	  show	  that	  NUAK1	   is	   required	   for	  both	  
initiation	   and	   maintenance	   of	   autochthonous	   colorectal	   tumors.	   NUAK1	   facilitates	   nuclear	  
translocation	  of	   the	  anti-­‐oxidant	  master	   regulator	  NRF2	  by	   counteracting	  negative	   regulation	  of	  
NRF2	   by	   GSK3β.	   Depletion	   or	   inhibition	   of	   NUAK1	   thus	   renders	   human	   CRC	   cells	   and	   murine	  
colorectal	   tumors	  vulnerable	   to	  oxidative	  stress-­‐induced	  cell	  death.	  Our	  data	   reveal	  NUAK1	  as	  a	  
candidate	  therapeutic	  target	  in	  human	  CRC.	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Results	  
	  
Nuak1	  overexpression	  is	  associated	  with	  worse	  outcome	  in	  human	  CRC	  
We	  used	   RNA-­‐Scope	   in	   situ	   hybridization	   to	   examine	  NUAK1	   expression	   in	   a	   660-­‐sample	   tissue	  
microarray	  of	  human	  CRC	   (19).	  NUAK1	   is	  weakly	  expressed	   in	  normal	  human	  colonic	  epithelium	  
but	  increased	  expression	  is	  significantly	  enriched	  in	  aggressive	  (Dukes’	  stage	  B	  &	  C)	  CRC	  (Fig.	  1A	  &	  
S1A,	   B).	   In	   silico	   examination	   of	   the	   TCGA	   Colorectal	   adenocarcinoma	   cohort	   similarly	   showed	  
significantly	  elevated	  NUAK1	  expression	   in	  advanced	  (T	  stage	  3	  &	  4)	  versus	  early	  (T	  stage	  1	  &	  2)	  
disease,	   and	   in	   patients	  with	   lymph	  node	  metastasis	   versus	   none	   (Fig.	   1B).	  Meta-­‐analysis	   of	   17	  
independent	   cohorts	   comprising	   947	   human	   CRC	   samples,	   via	   SurvExpress	   (20),	   also	   revealed	  
significantly	   higher	   NUAK1	   expression	   in	   the	   high	   versus	   low	   risk	   group,	   and	   elevated	   NUAK1	  
expression	  was	   associated	  with	   significantly	   reduced	   overall	   survival	   and	   a	   hazard	   ratio	   of	   1.49	  
(Fig.	  1C,	  D).	  A	  similar	  reduction	  of	  overall	  survival	  was	  borne	  out	  by	  individual	  analysis	  of	  two	  large	  
cohorts	   in	   which	   the	   outcome	   for	   the	   majority	   of	   patients	   was	   known	   (Fig.	   S1C-­‐F)	   (21,	   22).	  	  
Elevated	  NUAK1	  expression	  thus	  correlates	  with	  worse	  outcome	  in	  colorectal	  cancer.	  
	   We	   therefore	   examined	   the	   functional	   requirement	   for	   NUAK1	   in	   human	   CRC	   cell	   lines	  
using	  2	  previously	  described	  highly-­‐selective	  NUAK1	  inhibitors,	  HTH-­‐01-­‐015	  and	  WZ4003.	  HTH-­‐01-­‐
015	  is	  reported	  to	  show	  little-­‐to-­‐no	  activity	  towards	  AMPK	  or	  other	  related	  kinases	  while	  WZ4003	  
selectively	  inhibits	  both	  NUAK1	  and	  the	  closely	  related	  NUAK2	  (23).	  Overexpression	  of	  NUAK1	  and	  
NUAK2	   in	   human	  CRC	   tends	   to	   be	  mutually	   exclusive	   and	   accordingly	  we	   detected	   a	   reciprocal	  
pattern	  of	  NUAK	  protein	  expression	   in	  CRC	  cell	   lines	  (Fig.	  S1G,	  H).	  Treatment	  with	  5µM	  HTH-­‐01-­‐
015	   suppressed	   proliferation	   of	   multiple	   cell	   lines	   and	   this	   effect	   was	   reproduced	   by	   RNAi-­‐
mediated	   depletion	   of	   NUAK1	   (Fig.	   S1I-­‐L).	   Strikingly,	   treatment	   with	   10µM	   HTH-­‐01-­‐015	   was	  
profoundly	  toxic	  in	  the	  same	  cell	  lines	  and	  correlated	  with	  a	  stronger	  reduction	  in	  phosphorylation	  
of	  the	  NUAK1/NUAK2	  substrate,	  MYPT1,	  even	  in	  cells	  that	  express	  very	  low	  levels	  of	  NUAK1	  (Fig.	  
1E,	  F).	  This	  cytotoxic	  effect	  was	  also	  observed	  using	  the	  dual	  NUAK	  inhibitor	  WZ4003,	  suggesting	  it	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reflects	   on-­‐target	   activity	   of	   the	   inhibitors.	   Notably,	   WZ4003	   gave	   greater	   suppression	   of	   p-­‐
MYPT1S445,	  consistent	  with	  dual	   inhibition	  of	  NUAK1	  and	  NUAK2,	  and	  showed	  somewhat	  greater	  
potency,	  driving	  significant	  cell	  death	  at	  5µM	  in	  SW480	  cells	  (Fig.	  S1M,	  N).	  Inhibition	  of	  NUAK1	  is	  
thus	  sufficient	  to	  drive	  apoptosis	  in	  CRC	  cells	  and	  death	  does	  not	  require	  complete	  suppression	  of	  
MYPT1S445	  phosphorylation.	   In	  contrast	  with	   the	  CRC	   lines,	  wild-­‐type	  MEFs	  and	  U2OS	  cells	  were	  
comparatively	  resistant	  to	  both	  inhibitors,	  especially	  to	  the	  NUAK1-­‐selectve	  HTH-­‐01-­‐015	  (Fig.1G	  &	  
S1O,	  P),	  consistent	  with	  previous	  data	  showing	  that	  U2OS	  are	  refractory	  to	  NUAK1	  depletion	  (9).	  
Notably,	  both	   inhibitors	  completely	   suppressed	  MYPT1	  phosphorylation	   in	  U2OS,	   indicating	   that	  
NUAK1	   accounts	   for	   the	   vast	   majority	   of	   MYPT1S445	   phosphorylation	   in	   this	   cell	   type.	   As	   we	  
showed	  previously	   in	  MEFs	   (5),	  overexpression	  of	  MYC	  strongly	  sensitized	  U2OS	  to	  HTH-­‐01-­‐015-­‐
induced	   apoptosis	   (Fig.	   1H).	   Conversely,	   depletion	   of	   endogenous	  MYC	   rescued	   CRC	   cells	   from	  
HTH-­‐01-­‐015-­‐induced	   apoptosis	   and	   rescue	   was	   proportional	   to	   the	   degree	   of	   MYC	   depletion,	  
consistent	  with	  an	  ectopic	  requirement	  for	  NUAK1	  in	  cells	  with	  deregulated	  MYC	  (Fig.	  1I).	  
	  
Nuak1	  is	  required	  for	  formation	  of	  colonic	  polyps	  in	  mice	  
In	  order	  to	  investigate	  the	   in	  vivo	  requirement	  for	  NUAK1	   in	  CRC,	  we	  bred	  mice	  bearing	  a	  floxed	  
Nuak1	   allele	   (Nuak1FL/FL)	   (11)	   onto	   a	   Tamoxifen	   (Tam)-­‐inducible	   mouse	   model	   of	   sporadic	  
intestinal	  cancer:	  Villin-­‐CreERT2;	  APCFL/+;lsl-­‐KRasG12D	   (VAK	  for	  short).	   In	  this	  model,	  transient	  Tam-­‐
dependent	  activation	  of	  CreERT2	  in	  the	  intestines	  of	  adult	  mice	  drives	  widespread	  deletion	  of	  one	  
copy	   of	   Apc	   simultaneous	   with	   expression	   of	   oncogenic	   KRasG12D,	   however,	   tumor	   formation	  
requires	  stochastic	  loss	  of	  the	  second	  copy	  of	  Apc	  (Fig.	  S2A).	  	  In	  the	  absence	  of	  mutant	  KRas,	  Apc	  
null	  polyps	  are	  largely	  restricted	  to	  the	  small	   intestine,	  whereas	  in	  the	  presence	  of	  mutant	  KRas,	  
adenomas	  form	  in	  both	  large	  and	  small	  intestine	  (19).	  	  	  
	   Using	   a	   single	   injection	   of	   Tam	   to	   transiently	   activate	   CreERT2,	  we	   deleted	   Nuak1	   in	   the	  
intestines	   of	   adult	   Villin-­‐CreERT2;	   APCFL/+;lsl-­‐KRasG12D;Nuak1FL/FL	  mice	   (VAKN	   for	   short)	   and	   aged	  
Port	  et	  al.	  
	   7	  
mice	  until	  symptomatic	  in	  order	  to	  compare	  the	  intestinal	  tumor	  burden	  with	  that	  of	  symptomatic	  
VAK	   mice.	   	   Deletion	   of	   Nuak1	   profoundly	   suppressed	   both	   the	   number	   and	   size	   of	   individual	  
tumors	  in	  the	  colon	  of	  VAKN	  mice,	  compared	  to	  VAK	  controls	  (Fig.	  2A-­‐D).	  	  In	  contrast,	  we	  observed	  
no	  significant	  difference	   in	  either	  the	  number	  or	  size	  of	   tumors	  that	  arose	   in	  the	  small	   intestine	  
(SI),	  and	  VAKN	  mice	  required	  sacrifice	  concurrently	  with	  VAK	  mice	  (Fig.	  S2B-­‐D).	  	  However,	  Q-­‐PCR	  
analysis	   of	  Nuak1	   expression	   in	   individual	   polyps	   harvested	   from	   the	   SI	   of	   VAKN	  mice	   revealed	  
enrichment	   of	   Nuak1	   mRNA	   when	   compared	   with	   disease-­‐free	   adjacent	   tissue	   (Fig.	   S1E),	  
indicating	  a	  failure	  of	  transient	  CreER	  activation	  to	  efficiently	  delete	  Nuak1	  in	  the	  tumor	  initiating	  
population	  of	  the	  small	  intestine.	  The	  absence	  of	  a	  Nuak1FL/FL	  phenotype	  in	  SI	  tumors	  thus	  appears	  
to	  reflect	  technical	  failure	  but	  is	  of	  little	  clinical	  relevance	  given	  the	  rarity	  of	  SI	  tumors	  in	  human	  
populations.	  Colonic	  tumors	  in	  VAKN	  mice	  presented	  with	  comparable	  levels	  of	  nuclear	  β-­‐Catenin	  
and	   sporadic	   phospho-­‐Erk1/2	   staining,	   as	   compared	   with	   VAK	   tumors	   (Fig.	   S2F),	   however,	   all	  
tumors	   arising	   in	   VAKN	  mice	   retained	   detectable	   expression	   of	  Nuak1	   mRNA	   (see	   Fig.	   S2G	   for	  
examples),	   suggesting	   a	   selective	   pressure	   to	   retain	   Nuak1	   in	   colonic	   tumor	   epithelium.	  
Importantly,	   deletion	  of	  Nuak1	   in	   otherwise	  wild-­‐type	  mice	  had	  no	   apparent	   effect	   on	   small	   or	  
large	  intestine	  architecture	  or	  function	  (Fig.	  S3A-­‐C),	  suggesting	  that	  the	  requirement	  for	  Nuak1	  in	  
the	  adult	  gut	  is	  restricted	  to	  transformed	  tissue.	  
	  
Nuak1	  activity	  is	  required	  for	  ex-­‐vivo	  spheroid	  formation	  
Homozygous	   deletion	   of	   Apc	   (AHom)	   in	   the	   gut	   rapidly	   gives	   rise	   to	   a	   Myc-­‐dependent	   “crypt	  
progenitor”	   phenotype,	   characterized	   by	   an	   extension	   of	   the	   transit-­‐amplifying	   population	   into	  
the	  normally	  quiescent	  villi	  of	  the	  small	  intestine	  (17).	  This	  phenotype	  was	  unimpaired	  by	  deletion	  
of	   Nuak1	   in	   VAHomN	   intestines	   (Fig.	   S3D).	   VAHomK	   transformed	   gut	   epithelium	   gives	   rise	   to	  
spheroids	  when	  cultured	  in	  3D	  ex	  vivo,	  reflecting	  the	  tumor-­‐initiating	  capacity	  of	  the	  transformed	  
tissue	   (24).	   Primary	   VAHomKN	   colonic	   epithelium	   showed	   reduced	   spheroid-­‐generating	   capacity,	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compared	  to	  VAHomK	  epithelium	  (Fig.	  2E	  &	  F).	  Nuak1	  expression	  was	  clearly	  detectable	  in	  the	  few	  
VAHomKN	   spheroids	   that	   grew,	   suggesting	   that	   they	   likely	   arose	   from	   cells	   that	   escaped	   Cre-­‐
mediated	   Nuak1	   deletion	   (Fig.	   2G).	   Interestingly,	   a	   similar	   reduction	   in	   spheroid-­‐generating	  
capacity	  was	  also	  observed	   in	  primary	  epithelium	  isolated	  from	  the	  small	   intestine	  (Fig.	  2E	  &	  F).	  	  
Accordingly,	  pharmacological	   inhibition	  of	  Nuak1	  with	  either	  HTH-­‐01-­‐015	  or	  WZ4003	  profoundly	  
suppressed	  formation	  of	  spheroids	  by	  VAHomK	  gut	  epithelium	  from	  both	  small	  and	  large	  intestine	  
(Fig.	  2H	  &	  I),	  whereas	  wild-­‐type	  organoids	  were	  refractory	  to	  treatment	  over	  the	  same	  time	  frame	  
(Fig.	  S3E).	  
	  
NUAK1	  regulates	  the	  NRF2-­‐dependent	  oxidative	  stress	  response	  
Reasoning	   that	   key	   physiological	   roles	   of	   NUAK1	   would	   be	   conserved	   across	   cell	   types,	   we	  
exploited	   the	   fact	   that	  U2OS	   cells	   are	   refractory	   to	  NUAK1	   suppression	   (in	   the	  absence	  of	  MYC	  
overexpression)	  and	  express	  very	  little	  NUAK2,	  and	  performed	  an	  unbiased	  transcriptomic	  analysis	  
after	  RNAi-­‐mediated	  depletion	  of	  NUAK1.	  Metacore	  GeneGO	  pathway	  analysis	  revealed	  regulation	  
of	   cholesterol	   synthesis,	   cell	   adhesion,	   and	   glutathione	   metabolism	   amongst	   the	   topmost	  
pathways	   modulated	   upon	   NUAK1	   depletion	   (Fig.	   3A).	   The	   role	   of	   NUAK1	   in	   regulating	   cell	  
adhesion	   via	   phosphorylation	  of	  MYPT1	  was	  described	  previously	   (10),	  while	   the	  modulation	  of	  
glutathione	  metabolism	  suggested	  a	  novel	   role	   for	  NUAK1	   in	   the	  anti-­‐oxidant	  defense	  pathway.	  
Strikingly,	  our	  transcriptomic	  analysis	  revealed	  a	  coordinated	  reduction	  in	  expression	  of	  a	  host	  of	  
genes	  that	  are	  regulated	  by	  the	  anti-­‐oxidant	  transcription	  factor	  NRF2	  (NFE2L2)	  (25),	  including	  the	  
catalytic	  and	  regulatory	  subunits	  of	   the	  Glutamate-­‐Cysteine	  Ligase;	  ROS	  scavengers	  Thioredoxin,	  
Peroxiredoxin	  and	  MGST;	  and	  Glutathione	  Reductase	  (Fig.	  3B	  &	  S4A).	  	  Acute	  inhibition	  of	  NUAK1	  in	  
U2OS	  cells	  with	  HTH-­‐01-­‐015	  recapitulated	  these	  results	  (Fig.	  3C),	  as	  did	  CRE-­‐mediated	  deletion	  of	  
Nuak1	   in	  primary	  MEFs	  (Fig.	  S4B,	  C),	  confirming	  the	  conservation	  of	  this	  effect	  across	  cells	  types	  
and	   species.	   	  RNA-­‐SEQ	  analysis	  of	   SW480	  CRC	  cells	  upon	  depletion	  of	  NUAK1	   revealed	  a	   strong	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overlap	  with	   genes	  modulated	   upon	   depletion	   of	   NRF2	   (NFE2L2),	   including	   several	   anti-­‐oxidant	  
pathway	  genes	  and	  the	  miR17-­‐92	  cluster,	  recently	  shown	  to	  negatively	  regulate	  LKB1	  upstream	  of	  
NUAK1	   (26),	   suggestive	   of	   feedback	   regulation	   (Fig.	   3D,	   E).	   	   Similar	   results	   were	   obtained	   in	  
HCT116	  cells	  (Fig.	  3D).	  Pathway	  analysis	  showed	  broadly	  similar	  transcriptional	  effects	  of	  depletion	  
of	  either	  NUAK1	  or	  NRF2,	  while	  analysis	  of	  down-­‐regulated	  genes	  revealed	  significant	  enrichment	  
for	  pathways	  “Oxidative	  stress”	  and	  “NRF2	  regulation	  of	  oxidative	  stress”	  in	  both	  instances	  (Table	  
S1	  &	  S2).	  
The	  reduced	  expression	  of	  NRF2	  target	  genes	  suggested	  that	  NUAK1-­‐deficient	  cells	  would	  
be	  hypersensitive	  to	  oxidative	  stress.	  	  Accordingly,	  we	  detected	  elevated	  levels	  of	  cytosolic	  H2O2	  in	  
U2OS,	  multiple	  CRC	  cell	  lines,	  and	  VAK	  colonic	  spheroids,	  after	  acute	  treatment	  with	  HTH-­‐01-­‐015	  
(Fig.	  3F-­‐I),	  while	  depletion	  of	  NUAK1	  sensitized	  U2OS	  and	  multiple	  CRC	  cell	  lines	  to	  H2O2-­‐induced	  
cell	  death,	   consistent	  with	   the	   inhibitor	  and	  RNAi	  each	   reducing	  anti-­‐oxidant	  buffering	  capacity,	  
albeit	   to	   different	   degrees	   (Fig.	   3J).	   Similar	   sensitization	   to	   H2O2-­‐induced	   cell	   death	   was	   also	  
observed	  upon	  CRE-­‐mediated	  deletion	  of	  NUAK1	   in	  MEFs,	  providing	  genetic	  confirmation	  of	   the	  
specificity	  of	  this	  effect	  (Fig.	  S4D,	  E).	  CRC	  lines	  with	  lower	  levels	  of	  NUAK1	  were	  inherently	  more	  
sensitive	  to	  ROS-­‐induced	  cell	  death,	  even	  in	  the	  absence	  of	  NUAK1	  depletion,	  compared	  with	  cells	  
expressing	   higher	   levels	   of	   NUAK1,	   while	   the	   relatively	   modest	   sensitization	   of	   SW480	   cells	  
compared	  with	  U2OS	  cells	  may	  reflect	  differences	  in	  the	  efficiency	  of	  NUAK1	  depletion	  or	  indeed	  
the	   relative	   expression	   of	   NUAK2.	   Notably,	   depletion	   of	   NUAK1	   in	   some	   CRC	   lines	   resulted	   in	  
increased	   NUAK2	   expression	   (Fig.	   S1L).	   Importantly,	   provision	   of	   exogenous	   anti-­‐oxidants	  
significantly	   rescued	   human	   CRC	   cells	   (Fig.	   3K	   &	   S4F)	   and	   VAK	   spheroids	   (Fig.	   3L	   &	   S4G)	   from	  
NUAK1	   inhibitor-­‐induced	  apoptosis,	   indicating	  that	  ROS	  contributes	  substantially	   to	  cell	  death	   in	  
both	   settings.	   The	   remaining	   levels	   of	   cell	   death	   measured	   in	   the	   CRC	   cell	   lines	   likely	   reflects	  
exhaustion	  of	  the	  exogenous	  anti-­‐oxidant,	  evidenced	  by	  intermediate	  levels	  of	  ROS	  in	  cells	  treated	  
for	  8hrs	  with	  NUAK1	  inhibitor	  in	  the	  presence	  of	  Trolox	  (Fig.	  S4H,	  I).	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NUAK1	  promotes	  nuclear	  translocation	  of	  NRF2	  by	  antagonizing	  GSK3β 	  
NRF2	  was	   recently	   described	   to	   contain	   an	   AMPK-­‐substrate	   consensus	   phospho-­‐motif	   (27)	   that	  
could	  potentially	  be	  targeted	  for	  phosphorylation	  by	  NUAK1.	  We	  used	  immunoprecipitation	  (IP)	  of	  
Flag-­‐tagged	  NRF2	   followed	  by	   immunoblotting	  with	  a	  pan-­‐phospho-­‐AMPK-­‐substrate	  antibody	   to	  
assess	   the	   influence	   of	   NUAK1	   inhibition	   on	   NRF2	   phosphorylation	   levels	   but	   detected	   no	  
difference	  (Fig.	  S5A).	  Similarly,	  purified	  NUAK1	  showed	  no	  activity	  towards	  a	  corresponding	  NRF2	  
peptide	   in-­‐vitro	   (Fig.	   S5B).	   	   Thus,	   NRF2	   does	   not	   appear	   to	   be	   a	   direct	   target	   of	   NUAK1	   kinase	  
activity.	  
We	   noticed	   that	   acute	   inhibition	   of	   NUAK1	   resulted	   in	   decreased	   total	   NRF2	   levels	   (Fig.	  
4A).	   NRF2	   is	   regulated	   by	   KEAP1,	   which	   sequesters	   NRF2	   in	   the	   cytoplasm	   while	   targeting	   it	  
continuously	   for	   Ubiquitin-­‐dependent	   degradation	   (28,	   29).	   We	   asked	   if	   KEAP1	   is	   required	   for	  
regulation	   of	  NRF2	   by	  NUAK1.	   As	   expected,	   RNAi-­‐mediated	   depletion	   of	   KEAP1	   increased	   basal	  
levels	  of	  NRF2,	  yet	  concomitant	  inhibition	  of	  NUAK1	  continued	  to	  reduce	  total	  NRF2	  protein	  levels	  
(Fig.	  4B).	  Accordingly,	  cyclohexamide	  time-­‐course	  analysis	  showed	  that	  NUAK1	  depletion	  reduces	  
total	   NRF2	   levels	   but	   does	   not	   affect	   the	   rate	   of	   NRF2	   degradation,	   per	   se	   (Fig.	   S5C).	   KEAP1	  
contains	  a	  number	  of	  Cysteine	  residues	  that	  are	  subject	  to	  oxidation	  and,	  in	  the	  presence	  of	  ROS,	  
oxidized	  KEAP1	  releases	  NRF2	  allowing	  it	  to	  translocate	  to	  the	  nucleus	  and	  activate	  transcription	  
(30).	   We	   therefore	   examined	   NUAK1-­‐depleted	   or	   HTH-­‐01-­‐015-­‐treated	   U2OS	   cells	   for	   nuclear	  
accumulation	   of	   NRF2	   after	   acute	   treatment	   with	   H2O2	   and	   found	   that	   loss	   of	   NUAK1	   activity	  
strongly	   suppressed	   ROS-­‐induced	   nuclear	   accumulation	   of	   NRF2	   (Fig.	   4C).	   Accordingly,	   ROS-­‐
induced	   transcription	   of	   NRF2	   targets	  was	   also	   suppressed	   upon	   depletion	   of	   NUAK1	   (Fig.	   4D).	  
Analysis	   in	   multiple	   CRC	   cell	   lines	   likewise	   revealed	   that	   depletion	   of	   NUAK1	   suppresses	   ROS-­‐
driven	  NRF2	  nuclear	  accumulation,	  indicating	  that	  this	  role	  of	  NUAK1	  is	  conserved	  in	  CRC	  (Fig.	  4E	  
&	  S5D).	  Additionally,	   this	   role	  of	  NUAK1	   is	  at	   least	  partially	   shared	  with	  NUAK2,	  as	  depletion	  of	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NUAK2	  in	  SW620	  cells	  similarly	  suppressed	  peroxide-­‐induced	  nuclear	  accumulation	  of	  NRF2	  (Fig.	  
S5E).	  
We	   used	   unbiased,	   SILAC-­‐based	   phospho-­‐proteomics	   to	   identify	   candidate	  mediators	   of	  
NRF2	  regulation	  upon	  acute	  inhibition	  of	  NUAK1	  in	  U2OS	  cells	  (see	  schematic,	  Fig.	  S5F).	  	  Ser445	  of	  
MYPT1	  was	  the	  only	  site	  resident	  within	  a	  recognizable	  AMPK-­‐related	  kinase	  consensus	  motif	  that	  
was	   consistently	   reduced	   upon	  NUAK1	   inhibition.	   This	   analysis	   also	   revealed	   reduced	   inhibitory	  
phosphorylation	   of	   GSK3β	   at	   Ser9	   and	   a	   corresponding	   increase	   in	   phosphorylation	   of	  multiple	  
GSK3β	  targets	  (Fig.	  5A	  &	  Table	  S3).	  	  GSK3β	  is	  known	  to	  suppress	  nuclear	  accumulation	  of	  NRF2:	  In	  
the	   presence	   of	   oxidative	   stress,	   activation	   of	   AKT	   inhibits	   GSK3β	   via	   Ser9	   phosphorylation,	  
allowing	   nuclear	   accumulation	   of	   NRF2	   (31).	   We	   therefore	   examined	   the	   influence	   of	   NUAK1	  
depletion	   on	   ROS-­‐driven	   signal	   transduction	   via	   AKT	   and	   GSK3β.	   Treatment	   of	   U2OS	   cells	   with	  
H2O2	   rapidly	   activated	   AKT,	   leading	   to	   increased	   GSK3βS9	   phosphorylation.	   Upon	   depletion	   of	  
NUAK1,	   activation	   of	   AKT	   by	   H2O2	  was	   unimpaired,	   however,	   the	   inhibitory	   phosphorylation	   of	  
GSK3β	  was	  strongly	  reduced,	  suggesting	  that	  NUAK1	  may	  limit	  de-­‐phosphorylation	  of	  GSK3βS9	  (Fig.	  
5B).	  Similar	  results	  were	  observed	  upon	  H2O2	  treatment	  of	  NUAK1-­‐depleted	  SW480	  cells	  (Fig.	  5C),	  
while	  treatment	  with	  NUAK1	  inhibitor	  suppressed	  GSK3βS9	  phosphorylation	  in	  SW480	  cells	  and	  in	  
VAK	  LI	  spheroids	  (Fig.	  5D,	  E).	  Notably,	  phosphorylation	  of	  MYPT1	  by	  NUAK1	  inhibits	  PP1β	  activity	  
(10)	  and	  PP1β	  was	  previously	  shown	  to	  dephosphorylate	  GSK3β	  (32,	  33).	  Strikingly,	  H2O2	  led	  to	  a	  
clear	   increase	   in	   NUAK1-­‐dependent	   MYPT1	   phosphorylation	   (Fig.	   5B),	   suggesting	   that	   ROS	  
coordinately	  activates	  AKT	  and	  inactivates	  PP1β	  (via	  NUAK1)	  in	  order	  to	  suppress	  GSK3β activity.	  
Significantly,	  inhibition	  of	  GSK3β	  stabilized	  total	  NRF2	  levels	  and	  rescued	  nuclear	  accumulation	  of	  
NRF2	  in	  NUAK1-­‐deficienct	  SW480	  cells	  (Fig.	  5F	  &	  S5G).	   	   Interestingly,	  depletion	  of	  PTEN	  similarly	  
rescued	   nuclear	   NRF2,	   suggesting	   that	   the	   requirement	   for	   NUAK1	   in	   this	   pathway	   can	   be	  
overcome	  by	  strongly	  deregulated	  AKT	  signaling	  (Fig.	  S5H).	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Regulation	  of	  NUAK1	  by	  ROS	  and	  NRF2	  
We	  asked	  if	  NUAK1	  is	  an	  integral	  part	  of	  the	  oxidative	  stress	  response	  pathway.	  Depletion	  of	  NRF2	  
with	  2	   independent	   siRNAs	   consistently	   reduced	  NUAK1	  protein	   levels	   (Fig.	   6A).	   Examination	  of	  
the	   NUAK1	   promoter	   revealed	   a	   near-­‐consensus	   anti-­‐oxidant	   response	   element	   (ARE)	   located	  
approximately	   1.2kb	   upstream	   of	   the	   NUAK1	   transcription	   start	   site,	   and	   NRF2	   chromatin	   IPs	  
showed	  specific	  binding	  of	  NRF2	  to	  the	  putative	  NUAK1	  ARE,	  albeit	  at	  much	  lower	  efficiency	  than	  
to	   the	   canonical	  NRF2	   target,	  HMOX1	   (Fig.	   6B,	  C).	  Treatment	  of	  U2OS	   cells	  with	  H2O2	  modestly	  
increased	  NUAK1	  mRNA	  but	  had	  much	  greater	  influence	  on	  NUAK1	  protein,	  suggesting	  that	  post-­‐
translational	   regulation	   may	   have	   greater	   functional	   impact	   (Fig.	   6D,	   E).	   Time-­‐course	   analysis	  
revealed	   that	  H2O2	   treatment	   rapidly	   increased	  activating	  phosphorylation	  of	  NUAK1	  at	   Thr211,	  
and	  consequent	  MYPT1S445	  phosphorylation,	  downstream.	  These	  changes	  occur	  within	   the	  same	  
time-­‐frame	  as	  increased	  AKT	  phosphorylation,	  known	  to	  result	  from	  direct	  inactivation	  of	  PTEN	  by	  
ROS	  (34),	  suggesting	  that	  ROS	  may	  directly	  modify	  NUAK1	  (Fig.	  6F).	  To	  investigate	  this	  hypothesis,	  
we	  first	  used	  Dimedone	  labeling	  (35)	  of	  cells	  expressing	  FLAG-­‐tagged	  NUAK1	  to	  measure	  Cysteine	  
oxidation	   after	   H2O2	   treatment:	   Treatment	   with	   increasing	   doses	   of	   H2O2	   resulted	   in	   increased	  
Dimedone	   labeling	   of	   FLAG-­‐immunoprecipitated	   NUAK1	   (Fig.	   6G).	   Consistently,	   MS	   analysis	   of	  
Iodo-­‐acetamide	   labeling	  of	  FLAG-­‐NUAK1	   IPs	   from	  cells	   treated	   for	  5	  minutes	  with	  H2O2	   similarly	  
revealed	   increased	  oxidation	  of	  multiple	  NUAK1	  Cysteines,	  as	  compared	  with	  untreated	  controls	  
(Fig.	   6H).	   Collectively,	   our	   data	   suggest	   a	   model	   wherein	   ROS-­‐dependent	   activation	   of	   NUAK1	  
coordinates	  inhibition	  of	  PP1β	  with	  activation	  of	  AKT	  in	  order	  to	  counteract	  suppression	  of	  nuclear	  
NRF2	  by	  GSK3β	  (Fig.	  6I).	  
	  
Modeling	  the	  therapeutic	  potential	  of	  Nuak1	  suppression	  in	  vivo	  
The	   above	   data	   collectively	   suggest	   that	   NUAK1	   may	   be	   an	   excellent	   target	   for	   therapeutic	  
intervention	   in	  CRC.	   	  However,	   the	   relatively	  poor	  potency	  of	   the	  NUAK1	   inhibitors	  used	  above	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preclude	  their	  use	  in	  vivo.	  	  We	  therefor	  employed	  a	  doxycycline-­‐inducible	  RNAi	  approach	  to	  assess	  
the	   impact	   of	   acute	  Nuak1	   suppression	   on	   pre-­‐existing	   tumors.	  We	   used	   Villin-­‐CreERT2	   to	   limit	  
expression	  of	  rtTA3	  to	  the	  mouse	  intestine.	  Upon	  activation	  with	  doxycycline	  (Dox),	  rtTA3	  was	  then	  
used	   to	   drive	   expression	   of	   either	   of	   2	   shRNAs,	   targeting	  Nuak1	  mRNA	   from	  nucleotide	   612	   or	  
1533	  respectively,	  stringently	  selected	  to	  specifically	  deplete	  Nuak1	  as	  previously	  described	  (see	  
Supplementary	  Methods).	   Figure	   S6A	   shows	   depletion	   of	   NUAK1	   in	  MEFs	   upon	  Dox-­‐dependent	  
expression	  of	  Nuak1	  shRNA.	  
Tumors	   were	   initiated	   in	   heterozygous	   floxed	   Apc	   (VA)	   mice	   by	   Tamoxifen-­‐dependent	  
activation	   of	   CreERT2,	   and	   tumor	   development	   in	   the	   colon	  was	   accelerated	   by	   treatment	  with	  
dextran	  sulfate	  sodium	  salt	   (DSS).	  DSS-­‐treated	  VA	  mice	  develop	  colonic	  polyps	  within	  70	  days	  of	  
CreERT2	   activation	   with	   >90%	   penetrance	   (36),	   and	   this	   time	   post-­‐induction	   was	   chosen	   to	  
commence	  Dox-­‐dependent	   induction	  of	  either	  shRNA.	  Mice	  were	  maintained	  on	  Dox	  for	  1	  week	  
then	   harvested	   for	   analysis	   (for	   a	   schematic,	   see	   Fig.	   S6B).	   DSS-­‐treated	   VA	  mice	   lacking	   either	  
Nuak1	   shRNA	   or	   rtTA	   alleles	   were	   similarly	   administered	   Dox,	   to	   control	   for	   effects	   of	   the	  
antibiotic.	   Depletion	   of	  Nuak1	   for	   just	   one	   week	   strongly	   reduced	   the	   number	   of	   tumors	   per	  
mouse	  and	  moreover	  suppressed	  the	  size	  of	  the	  remaining	  tumors	  found	  upon	  examination	  (Fig.	  
7A).	   Similar	   results	  were	   obtained	  with	   both	  Nuak1	   shRNA	   alleles,	   strongly	   suggesting	   that	   the	  
observed	  effects	  reflect	  the	  “on-­‐target”	  depletion	  of	  Nuak1.	  Of	  the	  tumors	  that	  persisted	  in	  Nuak1	  
shRNA-­‐expressing	  mice,	  all	  expressed	  readily	  detectable	   levels	  of	  Nuak1	  mRNA,	  as	  measured	  by	  
ISH	   (Fig.	   S6C),	   indicating	   that	   some	   tumors	   escape	   shRNA-­‐mediated	   Nuak1	   depletion.	   PEARL	  
imaging	  of	   intestines	  of	  mice	   injected	  overnight	  with	   Licor	  ROSstarTM	   reagent	   revealed	  elevated	  
ROS	   levels	   in	   colonic	   tumors	   in	   situ	   after	   just	   2	   days	   of	   NUAK1	   depletion	   (Fig.	   S6D)	   while	   IHC	  
analysis	   showed	   increased	   oxidative	   damage	   (8-­‐oxo-­‐dG),	   increased	   apoptosis	   (TUNEL),	   and	  
reduced	  proliferation	   (BrdU)	   in	  NUAK1-­‐depleted	   tumors	  within	   the	  same	   timeframe	   (Fig.	  7B,	  C).	  
Consistent	   with	   our	   in	   vitro	   data,	   transcriptomic	   analysis	   of	   NUAK1-­‐depleted	   tumors	   revealed	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significantly	  reduced	  expression	  of	  a	  host	  of	  NRF2	  target	  genes	  within	  2	  days	  of	  NUAK1	  depletion	  
(Fig.	  S6E).	  Importantly,	  exogenous	  provision	  of	  the	  antioxidant	  N-­‐Acetyl-­‐Cysteine	  (NAC)	  in	  drinking	  
water	  reversed	  the	  tumor	  suppressive	  effect	  of	  Nuak1	  depletion	  (Fig.	  7D	  &	  S6F),	  but	  had	  no	  effect	  
on	  Nuak1-­‐replete	  tumors	  (Fig.	  S6G).	  	  We	  conclude	  from	  these	  results	  that	  impairment	  of	  cellular	  
anti-­‐oxidant	  defenses	  is	  the	  underlying	  mechanism	  of	  the	  tumoricidal	  effect	  of	  Nuak1	  suppression	  
in	  the	  gut.	  
	  
Discussion	  
Here	   we	   demonstrate	   that	   the	   AMPK-­‐related	   kinase	   NUAK1	   plays	   a	   key	   role	   in	   protecting	  
colorectal	   tumors	   from	   oxidative	   stress.	   Using	   a	   combination	   of	   genetic	   and	   pharmacological	  
approaches,	  we	   show	   that	  Nuak1	   is	   required	   for	  both	   formation	  and	  maintenance	  of	   colorectal	  
tumors	   after	   loss	   of	   Apc;	   that	   suppression	   of	  NUAK1	   reduces	   viability	   of	   transformed	   intestinal	  
spheroids	  and	  of	  human	  colorectal	  cell	  lines;	  and	  that	  protecting	  cells	  from	  toxic	  levels	  of	  ROS,	  via	  
facilitation	  of	  NRF2-­‐dependent	  anti-­‐oxidant	  gene	  expression,	  is	  a	  key	  tumor-­‐promoting	  activity	  of	  
NUAK1.	   We	   show	   that	   NUAK1	   kinase	   activity	   is	   rapidly	   increased	   by	   ROS	   following	   Cysteine	  
oxidation	   and,	   moreover,	   that	   NUAK1	   is	   transcriptionally	   regulated	   by	   NRF2,	   placing	   NUAK1	  
squarely	  within	  the	  oxidative	  stress	  response	  pathway.	  Noting	  that	  NUAK1	  expression	  is	  normally	  
highest	  in	  highly	  oxidative	  tissues	  (11)	  it	  thus	  appears	  that	  protecting	  cells	  from	  oxidative	  stress	  is	  
a	   major	   physiological	   role	   of	   NUAK1	   that	   has	   been	   co-­‐opted	   by	   tumor	   cells	   to	   support	   their	  
survival	   in	   the	   typically	   harsh	   tumor	   microenvironment.	   AMPK	   also	   participates	   in	   antioxidant	  
defense	  albeit	  indirectly,	  by	  conserving	  NADPH	  levels	  via	  inhibition	  of	  lipid	  biosynthesis	  (37),	  and	  a	  
recent	  paper	  has	  shown	  a	  genetic	  requirement	  for	  this	  activity	  in	  MYC-­‐overexpressing	  melanoma	  
(38).	   	  Although	  AMPK	  may	  under	  certain	  circumstances	  directly	  phosphorylate	  NRF2	  (27),	   in	  our	  
system,	   the	   observed	   level	   of	   NRF2	   phosphorylation	   is	   extremely	   low	   and	   is	   not	  modulated	   by	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NUAK1	  inhibition.	  As	  such,	  AMPK	  does	  not	  presently	  appear	  to	  contribute	  to	  regulation	  of	  NRF2	  by	  
NUAK1.	  
	   Instead,	  we	  show	  that	  NUAK1	  facilitates	  nuclear	  import	  of	  NRF2	  by	  counteracting	  negative	  
regulation	   of	   this	   process	   by	   GSK3β,	   and	   that	   direct	   inhibition	   of	   GSK3β	   restores	  NRF2	   nuclear	  
import	   in	   NUAK1-­‐deficient	   cells.	   ROS	   inactivation	   of	   PTEN	   activates	   AKT,	   resulting	   in	   direct	  
inhibitory	  phosphorylation	  of	  GSK3β	  on	  Ser9	   (31,	  39).	  This	  phosphorylation	   is	  opposed	  by	  PP1β,	  
which	   reactivates	  GSK3β	   (33).	  We	   show	   that	   activation	   of	   AKT	   by	   ROS	   is	   unaffected	   by	  NUAK1	  
suppression,	  however,	  AKT-­‐dependent	  regulation	  of	  GSK3β	   is	  facilitated	  by	   inhibition	  of	  PP1β	  by	  
NUAK1	   via	   phosphorylation	   of	   the	   PP1β	   regulatory	   subunit	  MYPT1.	   	   NUAK1	   is	   thus	   required	   to	  
coordinate	  inhibition	  of	  PP1β	  with	  AKT	  activation	  in	  response	  to	  ROS,	  thereby	  allowing	  GSK3β	  to	  
be	   switched	   off	   long	   enough	   to	   permit	   NRF2	   nuclear	   accumulation,	   providing	   fascinating	   new	  
insight	  into	  temporal	  coordination	  of	  Redox	  signal	  transduction.	  This	  role	  of	  NUAK1	  is	  likely	  to	  be	  
shared	   with	   NUAK2,	   which	   similarly	   suppresses	   PP1β	   via	   MYPT1,	   and	   indeed,	   we	   show	   that	  
depletion	  of	  NUAK2	  similarly	  reduces	  nuclear	  NRF2	  in	  cells	  that	  highly	  express	  NUAK2.	  However,	  
further	  work	  is	  needed	  to	  distinguish	  between	  specific	  effects	  of	  NUAK1	  and	  NUAK2	  on	  PP1β	  and	  
beyond.	  
	   This	  mechanism	  of	  regulation	  suggests	  that	  the	  effects	  of	  NUAK1	  suppression	  may	  be	  quite	  
pleiotropic	  and	  indeed,	  our	  phosphor-­‐proteomic	  analysis	  indicated	  modulation	  of	  multiple	  GSK3β	  
targets	  in	  addition	  to	  NRF2.	  Moreover,	  transcriptional	  regulation	  by	  NRF2	  reaches	  far	  beyond	  anti-­‐
oxidant	  gene	  expression,	  as	  previously	  noted	  (25).	  However,	  the	  central	  role	  of	  NRF2-­‐dependent	  
anti-­‐oxidant	   gene	   expression	   in	   supporting	   tumor	   cell	   viability	   is	   attested	   to	   1)	   by	   the	  
hypersensitivity	  of	  NUAK1-­‐depleted	  CRC	  tumor	  lines	  to	  oxidative	  stress-­‐induced	  apoptosis	  and	  2)	  
by	   the	  dramatic	   rescue	  of	  NUAK1-­‐depleted	  colonic	   tumors	  and	   inhibitor-­‐treated	  spheroids	  upon	  
provision	  of	  exogenous	  anti-­‐oxidants.	  The	  more	  modest	  (but	  nonetheless	  significant)	  anti-­‐oxidant	  
rescue	  observed	  in	  HTH-­‐01-­‐015-­‐treated	  CRC	  cells	  likely	  reflect	  the	  limits	  of	  trying	  to	  buffer	  against	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oxidative	   stress	   in	   standard	   cell	   culture	   (40).	   Although	   attempts	   to	   recapitulate	   the	   cytotoxic	  
effects	  of	  NUAK1	  inhibition	  in	  CRC	  cells	  using	  RNAi	  were	  unsuccessful,	  we	  believe	  that	  the	  effects	  
of	   HTH-­‐01-­‐015	   are	   specific	   for	   NUAK1	   for	   several	   reasons:	   1)	   This	   compound	   has	   been	   tested	  
against	  over	  120	  kinases	  and	  is	  extremely	  selective	  for	  NUAK1,	  although	  at	  higher	  concentrations	  
it	   does	   show	   some	   activity	   towards	   NUAK2	   and	   possibly	  MARK3	   (23);	   2)	   Cytotoxicity	   was	   only	  
observed	   at	   concentrations	   that	   yielded	   a	   clear	   reduction	   in	   MYPT1	   phosphorylation,	   thus	  
indicating	   greater	   suppression	   of	   either	   NUAK1	   or	   a	   NUAK1-­‐like	   activity;	   3)	   cytotoxicity	   was	  
reproducible	   with	   the	   unrelated	   compound	   WZ4003;	   4)	   consistent	   with	   our	   previous	  
demonstration	  of	  a	  synthetic	  lethal	  relationship	  between	  MYC	  &	  NUAK1	  (9),	  sensitivity	  to	  HTH-­‐01-­‐
015	  was	  MYC-­‐dependent	  and	  CRC	  cell	  death	  was	  rescued	  by	  MYC	  depletion.	  	  It	  is	  thus	  unclear	  why	  
cytotoxicity	   was	   not	   observed	   using	   RNAi	   in	   the	   cell	   culture	   setting,	   except	   in	   instances	   of	  
simultaneous	   peroxide	   challenge.	   It	   maybe	   that	   very	   low	   levels	   of	   residual	   NUAK1	   suffice	   to	  
suppress	  cell	  death,	  consistent	  with	  our	  data	  in	  SW620	  cells,	  which	  do	  express	  very	  low	  levels	  of	  
NUAK1.	  	  Additionally,	  the	  asynchronous	  nature	  of	  RNAi	  may	  allow	  cultured	  cell	  populations	  time	  
to	  quench	  H2O2	  before	  the	  threshold	  for	  loss	  of	  viability	  is	  breached	  and,	  accordingly,	  depletion	  of	  
NUAK1	  resulted	   in	  upregulation	  of	  NUAK2	   in	  multiple	  CRC	   lines,	   likely	  dampening	   the	   impact	  of	  
NUAK1	   depletion.	   	   Furthermore,	   HTH-­‐01-­‐015	   has	   been	   shown	   to	   partially	   inhibit	   NUAK2	   at	   the	  
10µM	  dose	  that	  exhibited	  cytotoxicity	  in	  CRC	  lines	  (23)	  and,	  while	  we	  cannot	  entirely	  exclude	  the	  
possibility	  of	  an	  off-­‐target	  effect	  of	   the	   inhibitor,	   the	   fact	   that	  CRC	  cytotoxicity	  at	   this	  dose	  was	  
significantly	  rescued	  by	  both	  anti-­‐oxidant	  provision	  and	  by	  depletion	  of	  c-­‐MYC	  strongly	  supports	  
our	   interpretation	  that	  the	  on-­‐target	  effect	  of	  the	   inhibitor	   is	  responsible	  for	   induction	  of	  tumor	  
cell	   death.	   	   The	  differential	   sensitivity	   of	   some	   cells	   (eg.	   SW480)	   to	   the	  NUAK1	   inhibitor	   versus	  
peroxide	  challenge	  after	  NUAK1	  depletion	  by	  RNAi	  may	  thus	  reflect	  expression	  of	  NUAK2	  and/or	  
the	  continued	  biochemical	  activity	  of	  residual	  levels	  of	  NUAK1	  after	  RNAi-­‐mediated	  depletion.	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   Our	   previous	   work	   linked	   the	   selective	   requirement	   of	   tumor	   cells	   for	   NUAK1	   to	   MYC	  
overexpression,	   and	   this	   link	   is	  borne	  out	  here	  by	   the	   rescue	  of	  NUAK1	   inhibitor-­‐induced	  death	  
upon	   depletion	   of	   MYC	   from	   CRC	   cell	   lines.	   In	   the	   intestine,	   loss	   of	   Apc	   leads	   to	   β-­‐Catenin-­‐
dependent	  overexpression	  of	  endogenous	  Myc.	  Although	  deregulated	  Myc	  is	  alone	  insufficient	  for	  
intestinal	   tumor	   formation	   (41),	   it	   is	   nonetheless	   required	   for	   β-­‐Catenin-­‐driven	   polyposis	   and,	  
significantly,	  is	  also	  required	  for	  the	  elevation	  of	  ROS	  levels	  observed	  in	  vivo	  upon	  loss	  of	  Apc	  (42).	  	  
Colorectal	   tumors	   will	   thus	   have	   evolved	   in	   the	   face	   of	   continuous	   oxidative	   stress	   and	   cells	  
derived	   therefrom	  would	   likely	  be	  better	  buffered	  against	  oxidative	   stress	   than	   cells	   (eg.	  U2OS)	  
that	   lack	   MYC	   deregulation.	   Accordingly	   we	   show	   that	   U2OS	   cells	   depleted	   of	   NUAK1	   are	  
exquisitely	  sensitive	  to	  a	  peroxide	  challenge	  and	  that	  this	  is	  phenocopied	  by	  MYC	  overexpression.	  	  
Note	  that	  the	  absence	  of	  NUAK2	  expression	  from	  U2OS	  cells	   likely	   increases	  their	   reliance	  upon	  
NUAK1.	   	  NUAK1	  thus	  functions	   in	  2	  major	  tumor-­‐protective	  pathways,	  ATP	  homeostasis	  and	  the	  
oxidative	  stress	  response,	  that	  are	  rapidly	  engaged	  to	  support	  viability	  upon	  MYC	  overexpression	  
(43).	   As	   such,	   NUAK1	   appears	   to	   be	   more	   intimately	   linked	   with	   the	   downstream	   metabolic	  
consequences	  of	  MYC	  deregulation	   than	  with	   the	  absolute	   levels	  of	  MYC	  protein	  per	   se	   and	  we	  
recently	   linked	  MYC	   deregulation	   to	   Calcium-­‐dependent	   activation	   of	   NUAK1	   in	   LKB1	   deficient	  
cells	  (13).	  
	   Exploiting	   the	   heightened	   sensitivity	   of	   tumor	   cells	   to	   ROS	   is	   emerging	   as	   a	   plausible	  
strategy	  for	  cancer	  therapy	  (44,	  45).	  Recently,	  intravenous	  injection	  of	  very	  high	  doses	  of	  di-­‐hydro-­‐
Ascorbate	  was	  shown	  to	  suppress	  colorectal	  tumor	  formation	  by	  saturating	  ROS	  scavengers,	  and	  
subsequent	   work	   suggests	   that	   this	   strategy	   may	   indeed	   show	   clinical	   benefit	   (46,	   47).	   With	  
increasing	   evidence	   linking	   elevated	   NRF2	   to	   aggressive	   disease	   (48,	   49),	   disabling	   anti-­‐oxidant	  
defenses	   via	   transient	   inhibition	   of	   NUAK1	  may	   offer	   a	   new	   strategy	   for	   improving	   therapeutic	  
outcomes	  in	  cancer.	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Materials	  &	  Methods	  
Mouse	  experiments	  and	  analyses	  
All	   experiments	   involving	  mice	  were	   approved	   by	   the	   local	   ethics	   committee	   and	   conducted	   in	  
accordance	  with	  UK	  Home	  Office	   license	   numbers	   70/7950	  &	   70/8646.	  Mice	  were	   housed	   in	   a	  
constant	  12hr	  light/dark	  cycle,	  and	  fed	  and	  watered	  ad	  libitum.	  Mice	  bearing	  doxycycline-­‐inducible	  
shRNAs	   targeting	   NUAK1	   are	   described	   in	   the	   supplementary	  materials	   section.	   	   All	  mice	  were	  
maintained	  on	  mixed	  (FVBN	  x	  C57Bl/6	  x	  129/SV)	  background	  and	  littermate	  controls	  were	  used	  for	  
all	   experiments.	   To	   induce	   allele	   recombination,	   transient	   activation	   of	   CreERT2	   in	   the	   intestine	  
was	   performed	   on	   mice	   aged	   6-­‐12	   weeks	   via	   single	   IP	   injection	   of	   50mg/kg	   Tamoxifen.	   	   For	  
survival	   analysis,	   humane	  end	  points	  were	  defined	   as	   exhibition	  of	   2	   or	  more	   symptoms:	   >15%	  
weight	   loss;	   pale	   feet;	   lethargy;	   bloody	   stool.	   Where	   indicated,	   1.75%	   dextran	   sodium	   sulfate	  
(DSS),	   m.w.	   35k-­‐50kDa	   (M.P.	   Biochemicals)	   was	   administered	   in	   drinking	   water	   for	   5	   days,	  
commencing	  4	  days	  post	  allele	  induction,	  followed	  by	  distilled	  water	  for	  1	  week,	  then	  tap	  water.	  	  
Doxycycline	  (Sigma;	  in	  H2O)	  was	  administered	  by	  oral	  gavage	  in	  2mg	  daily	  boluses,	  from	  day	  64	  to	  
day	   70	   post-­‐induction.	   	   N-­‐Acetyl-­‐Cysteine	   (Sigma;	   4%	   w/v	   soln.)	   was	   administered	   in	   drinking	  
water,	  starting	  3	  days	  before	  shRNA	  induction,	  and	  replaced	  every	  3-­‐4	  days	  until	  sacrifice.	  	  All	  mice	  
were	  sacrificed	  using	  a	  schedule	  1	  procedure.	  ROSstar	  650	  reagent	  (Licor)	  was	  injected	  IP	  the	  day	  
before	  tissue	  harvesting	  and	  signal	  was	  detected	  by	  PEARL	  imaging.	  
	  
Crypt	  culture	  
Primary	  spheroid	  cultures	  of	   intestinal	  crypts	  were	  established	  as	  previously	  described	  (50)	  from	  
the	   SI	   and	  Colon	  of	  VAHomK	  and	  VAHomKN	  mice:	   	  Adult	  mice	  were	   induced	  as	   above	  and	   tissues	  
harvested	  4	  days	   later.	   Intestines	  were	   flushed	  with	   ice-­‐cold	  PBS	  and	  opened	   longitudinally	  and	  
villi	  were	   removed	  using	  a	  glass	   coverslip.	   	   Intestines	  were	   incubated	   in	  EDTA/PBS	   (2mM	  for	  SI;	  
25mM	  for	  LI)	  for	  30min	  at	  4oC.	  	  Excess	  solution	  was	  discarded	  and	  loose	  intestine	  fragments	  were	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collected	   by	   manual	   trituration	   in	   3	   PBS	   washes.	   	   The	   crypt-­‐enriched	   fractions	   were	   passed	  
through	   a	   70µM	   cell	   strainer	   and	   pelleted	   at	   600rpm	   for	   2min	   in	   a	   table-­‐top	   centrifuge.	  	  
Resuspended	   crypts	  were	   counted	  by	   hemocytometer,	   then	   seeded	   in	  Matrigel	   (BD	  Bioscience)	  
with	   Advanced	   DMEM/F12	   media	   (Invitrogen),	   supplemented	   with	   10mM	   HEPES;	   2mM	  
Glutamine;	   0.1%	   FBS;	   Pen/Strep,	   N-­‐2	   &	   B-­‐27	   supplements	   (1X,	   Invitrogen).	   	   Alternatively,	   for	  
quantification	   of	   primary	   spheroid	   formation,	   isolated	   crypts	   were	   further	   incubated	   in	   Cell	  
Dissociation	   solution	   (Thermo)	   until	   a	   single	   cell	   suspension	   was	   achieved.	   Cells	   were	   then	  
counted	  and	  seeded	  at	  normalized	  density	  as	  above.	  	  Growth	  factors	  Noggin	  (100ng/ml)	  and	  EGF	  
(50ng/ml;	   Peprotech)	  were	   added	   to	   primary	   cultures	   but	   removed	   from	   subsequent	   passages.	  	  
Spheroids	  were	   counted	  manually	   3	  or	   4	  days	   after	   seeding.	   	  Wild-­‐type	  organoid	   cultures	  were	  
prepared	   similarly	   but	   additionally	   supplemented	   with	   R-­‐Spondin	   (500ng/ml;	   R&D	   systems).	  	  
Established	   crypt	   cultures	   were	   split	   1-­‐2	   times	   per	   week	   by	   manual	   disruption	   followed	   by	  
incubation	  in	  Cell	  Dissociation	  solution	  (Thermo)	  until	  a	  single	  cell	  suspension	  was	  achieved.	  	  Cells	  
were	   then	   counted	   and	   re-­‐seeded	   at	   normalized	   density.	   	   NUAK1	   inhibitors,	   HTH-­‐01-­‐015	   (Apex	  
Biotech)	  or	  WZ4003	   (Medchem	  Express)	   in	  DMSO,	  were	  added	   to	   single	   cell	   suspensions	  at	   the	  
indicated	   concentrations.	   Trolox	   [(±)-­‐6-­‐Hydroxy-­‐2,5,7,8-­‐tetramethylchromane-­‐2-­‐carboxylic	   acid]	  
(Sigma)	  was	  added	  to	  single	  cell	  suspensions	  at	  a	  final	  concentration	  of	  500µM	  for	  16hrs	  prior	  to	  
HTH-­‐01-­‐015	   and	   replenished	   daily	   for	   3	   days.	   ROS	   detection	   was	   performed	   by	   confocal	  
fluorescent	  microscopy	  using	  5µM	  CellRox	  green	  (Thermo;	  3hrs	  @	  37C)	  after	  overnight	  treatment	  
of	  pre-­‐formed	  spheroids	  with	  HTH-­‐01-­‐015.	  
	  
Cell	  Lines	  
U2OS	  (2009),	  HCT116,	  SW620	  &	  SW480	  (all	   in	  2013)	  cell	   lines	  were	  obtained	  from	  the	  ATCC	  and	  
cultured	  in	  DMEM	  supplemented	  with	  Penn/Strep	  &	  10%	  FBS.	  	  Cells	  were	  expanded	  initially	  upon	  
receipt	  and	  aliquoted	  into	  frozen	  stocks.	  	  Upon	  resuscitation,	  cells	  were	  passaged	  as	  required	  and	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discarded	   after	   no	   more	   than	   3	   months	   of	   continuous	   culture.	   Cell	   lines	   were	   periodically	  
validated	  using	   the	  Promega	  Geneprint	  10	  authentication	  kit,	  most	   recently	   in	  August	  2017.	   	  All	  
cell	  lines	  in	  culture	  were	  tested	  every	  3	  months	  for	  mycoplasma.	  
	  
Transcriptomic	  Analysis	  
Whole-­‐transcriptome	  analysis	  was	  performed	  by	  Illumina	  RNA-­‐Sequencing.	  	  The	  following	  datasets	  
are	   available	   through	   ArrayExpress:	   U2OS	   +/-­‐	   NUAK1	   shRNA,	   accession	   number	   E-­‐MTAB-­‐6244;	  
SW480	  +/-­‐	  siNRF2	  or	  siNUAK1,	  accession	  number	  E-­‐MTAB-­‐6264;	  Apc/DSS-­‐induced	  colonic	  tumors	  
+/-­‐	   shNUAK1,	   accession	  number	   E-­‐MTAB-­‐6265.	  A	   full	   description	  of	  methodology	   is	   provided	   in	  
the	  Supplementary	  Material.	  
	  
Statistical	  Analysis	  
All	   experiments	   were	   performed	   at	   least	   3	   times	   except	   where	   noted	   in	   the	   text.	   	   Raw	   data	  
obtained	  from	  quantitative	  Real	  Time	  PCR,	  FACS	  and	  spheroid	  generation	  assays	  were	  copied	  into	  
Excel	   (Microsoft)	   or	   Prism	   (Graphpad)	   spreadsheets.	   All	   Mean	   &	   SEM	   values	   of	   biological	  
replicates	  were	   calculated	   using	   the	   calculator	   function.	   	   Graphical	   representation	   of	   such	   data	  
was	  also	  produced	  in	  Excel	  or	  in	  Prism.	  	  Box	  &	  spider	  plots	  were	  generated	  using	  Prism.	  	  Statistical	  
significance	   for	   pairwise	   data	   was	   determined	   by	   the	   Student’s	   (Unpaired)	   or	   Paired	   T	   test,	   as	  
indicated.	   For	   multiple	   comparisons,	   ANOVA	   was	   used	   with	   a	   post-­‐hoc	   Tukey	   test.	   	   *	   denotes	  
P<0.05;	  **	  denotes	  P<0.01;	  ***	  denotes	  P<0.001.	   	  For	  Kaplan-­‐Meier	  plots,	  Mantel	  Cox	  logrank	  P	  
values	  are	  presented;	  for	  tumor	  enumeration,	  Mann	  Whitney	  tests	  were	  performed.	  
	  
Additional	  methods	  are	  described	  in	  the	  Supplementary	  Materials	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Figure	  Legends	  
Figure	  1:	  	  NUAK1	  overexpression	  correlates	  with	  tumor	  progression,	  lymph	  node	  infiltrates,	  and	  
reduced	  OS	  in	  human	  CRC	  
A)	  Summary	  of	  NUAK1	  mRNA	  detection	  in	  a	  human	  CRC	  TMA	  (N=660),	  sorted	  by	  Dukes’	  grade	  A-­‐C;	  	  
N=normal	  colon.	  	  Asterisks	  indicate	  significance	  (1-­‐way	  ANOVA	  &	  post-­‐hoc	  Tukey	  test).	  	  B)	  Box	  and	  
whisker	   plots	   of	   median-­‐centered	   NUAK1	   mRNA	   expression	   from	   the	   TCGA	   colorectal	  
adenocarcinoma	  cohort	  accessed	  via	  Oncomine:	  Left	  panel	  shows	  early	   (T1,2)	  versus	   late	   (T3,	  4)	  
stage	  CRC;	  right	  panel	  shows	  tumors	  with	  (N1,2)	  or	  without	  (N0	  lymph	  node	  metastasis.	  C)	  Overall	  
survival	  of	  human	  CRC	  patients	  (N=947)	  separated	  by	  high	  versus	  low	  NUAK1	  expression.	  	  Logrank	  
P	   value,	   hazard	   ratio	   (HR)	   and	   95%	   confidence	   interval	   (CI)	   shown.	  D)	   Box	   &	   whisker	   plots	   of	  
NUAK1	  mRNA	  levels	  in	  human	  CRC	  separated	  by	  risk	  group	  as	  per	  (C).	  T-­‐test	  P	  value	  shown.	  (C&D)	  
Data	   were	   mined	   and	   graphs	   adapted	   from	   Metabase	   SurvExpress.	   	   E)	   Apoptosis	   induced	   in	  
human	  CRC	  cell	  lines	  48hrs	  after	  treatment	  with	  the	  indicated	  concentrations	  of	  HTH-­‐01-­‐015.	  Red	  
bars	   indicate	   AnnexinV/Propidium	   Iodide	   (AV/PI)	   double	   positive	   cells;	   black	   bars	   indicate	  
AnnexinV	   positive	   cells.	   	   Mean	   and	   SEM	   of	   3	   independent	   experiments	   shown;	   asterisks	   show	  
significance	   (ANOVA	   &	   post-­‐hoc	   Tukey	   test,	   relative	   to	   vehicle	   treated	   controls	   (-­‐)).	   F)	  
Immunoblots	   of	   lysates	   from	   human	   CRC	   cell	   lines	   show	   reduction	   in	   MYPT1	   Ser445	  
phosphorylation	  upon	   inhibition	  of	  NUAK1	   (8hr).	   The	   asterisk	   indicates	   a	   non-­‐specific	   band.	   	  G)	  
Apoptosis	  induced	  in	  U2OS	  cells	  48hrs	  after	  treatment	  with	  10µM	  HTH-­‐01-­‐015	  or	  WZ4003.	  Mean	  
and	   SEM	  of	   3	   independent	   experiments	   shown;	   asterisks	   show	   significance	   (ANOVA	  &	  post-­‐hoc	  
Tukey	  test,	  relative	  to	  vc	  controls).	  Ns	  =	  not	  significantly	  increased	  relative	  to	  untreated	  controls.	  
Immunoblot	  (lower	  panel)	  shows	  suppression	  of	  p-­‐MYPT1S445	  upon	  NUAK1	  inhibition.	  H)	  Apoptosis	  
induced	  in	  U2OS-­‐MycER	  cells	  upon	  NUAK1	  inhibition	  in	  the	  presence	  (+	  OHT)	  or	  absence	  (-­‐	  OHT)	  of	  
4-­‐hydroxy-­‐tamoxifen-­‐dependent	   activation	   of	   overexpressed	   MycER.	   Mean	   and	   SEM	   of	   3	  
independent	  experiments	  shown;	  asterisks	  denote	  significance	   (2-­‐way	  ANOVA	  &	  post-­‐hoc	  Tukey	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test).	   	   Immunoblot	   shows	  nuclear	   stabilization	  of	  MycER	  by	  4-­‐OHT.	   	   I)	  Rescue	  of	  CRC	  cells	   from	  
HTH-­‐01-­‐015-­‐induced	   apoptosis	   upon	   depletion	   of	   MYC.	   	   Mean	   and	   SEM	   of	   a	   representative	  
experiment	  (N≥2)	  in	  each	  cell	  line	  shown;	  asterisks	  denote	  significance	  (ANOVA	  &	  post-­‐hoc	  Tukey	  
test.	  	  Immunoblots	  show	  depletion	  of	  MYC	  in	  the	  same	  cell	  lines	  (lower	  panels).	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Figure	  2:	  Deletion	  of	  Nuak1	  suppresses	  colorectal	  tumor	  formation	  
A)	   Number	   of	   large	   intestine	   (LI)	   tumors	   per	   mouse	   in	   VAK	   (N=12)	   and	   VAKN	   (N=16)	   mice,	  
harvested	  at	  end-­‐point.	  	  Black	  bar	  indicates	  Mean	  tumor	  number	  while	  red	  bars	  indicate	  SEM.	  	  B)	  
Total	  tumor	  burden	  (area)	  per	  mouse	  of	  the	  indicated	  genotypes.	  Mean	  &	  SEM	  shown.	  	  C)	  Size	  of	  
individual	   tumors	   in	  mice	  of	  the	   indicated	  genotypes.	  Box	  plots	  depict	  the	  median	  (red	  bar)	  and	  
interquartile	   range	   of	   individual	   tumor	   area;	   whiskers	   reflect	   maximum	   observed	   tumor	   size.	  
N=192	   (VAK)	  &	  119	   (VAKN).	   (A-­‐C)	   P	   values	   from	  Mann-­‐Whitney	   test	   shown.	   	  D)	  Representative	  
H&E	  stained	  images	  of	  tumors	  from	  VAK	  (top	  panels)	  and	  VAKN	  (lower	  panels)	  mice.	  	  Panels	  i-­‐iii:	  
scale	  bar	  =500µm.	  	  Panel	  iv:	  zoom	  of	  inset	  from	  iii,	  scale	  bar	  =200µm,	  T=tumor,	  N=normal	  tissue.	  
E)	   Number	   of	   spheroids	   arising	   from	   freshly	   isolated	   VAHomKN	   small	   and	   large	   intestine,	  
normalized	  to	  VAHomK	  controls	  seeded	  on	  the	  same	  day.	  Mean	  and	  SEM	  from	  VAHomK	  (N=4)	  and	  
VAHomKN	  (N=6)	  mice	  shown.	  ***	  denotes	  significance	  (Unpaired	  T-­‐test).	  F)	  Representative	  images	  
of	  spheroids	  from	  (E).	  Scale	  bar	  =500µm.	  	  G)	  Detection	  of	  Nuak1	  mRNA	  in	  colonic	  spheroids	  from	  
VAHomKN	  mice	   relative	   to	   Nuak1	   transcript	   levels	   in	   VAK	   spheroids.	   	   Mean	   of	   4	   VAHomK	   and	   6	  
VAHomKN	  mice	   shown.	   Error	   bar	   indicates	   SEM.	   	  H)	   Numbers	   of	   VAHomK	   small	   intestine-­‐derived	  
spheroids	  after	  treatment	  with	  Nuak1	   inhibitors	  HTH-­‐01-­‐015	  (HTH)	  or	  WZ4003	  (WZ),	  normalized	  
to	  vehicle	  treated	  control	  (vc).	  Mean	  &	  SEM	  of	  3	  independent	  experiments	  shown;	  asterisks	  show	  
significance	  (1-­‐way	  ANOVA	  &	  post-­‐hoc	  Tukey	  test,	  relative	  to	  vc	  controls).	  	  I)	  Numbers	  of	  VAHomK	  
large	  intestine-­‐derived	  spheroids	  treated	  and	  graphed	  as	  per	  (H).	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Figure	  3:	  NUAK1	  promotes	  NRF2-­‐dependent	  gene	  expression	  
A)	   Top	  10	  pathways	  modulated	   in	  U2OS	  cells	   after	  depletion	  of	  NUAK1	  by	   shRNA,	   identified	  by	  
Metacore	  GeneGO	  analysis	  of	  RNA-­‐Seq	  data.	  FDR	  =	  False	  discovery	  rate.	  B)	  RNA-­‐Seq	  read	  counts	  
of	   select	  NRF2	   targets	   from	   (A).	  Mean	  &	  SEM	  of	  3	  biological	   replicates	   shown;	  asterisks	  denote	  
significance	   (unpaired	   T-­‐test).	   	  C)	   Reduction	   of	   NRF2	   target	   gene	   expression	   upon	   inhibition	   of	  
NUAK1	  for	  8hrs	  in	  U2OS	  cells.	  Mean	  &	  SEM	  of	  3	  independent	  experiments	  shown;	  asterisks	  denote	  
significance	   (1-­‐tailed	   T	   test).	   D)	   Comparison	   of	   selected	   NRF2	   target	   gene	   expression	   upon	  
depletion	  of	  NRF2	  versus	  depletion	  of	  NUAK1	  in	  CRC	  cell	  lines,	  HCT116	  and	  SW480.	  	  N=4.	  	  Mean	  &	  
SEM	   shown;	   asterisks	   denote	   significance	   (Unpaired	   T-­‐test).	   E)	   Global	   analysis	   of	   the	  
transcriptomic	   impact	   of	   NRF2	   depletion	   versus	   NUAK1	   depletion	   in	   SW480	   cells.	   	   F)	   FACS	  
detection	   of	   cytosolic	   ROS	   levels	   by	   CellRox	   Deep	   RedTM	   staining	   of	   U2OS	   cells	   upon	   acute	  
inhibition	  of	  NUAK1.	  	  The	  upper	  panel	  shows	  a	  representative	  FACS	  graph;	  the	  lower	  panel	  shows	  
Mean	  ±	  SEM	  fluorescence	  intensity	  of	  HTH-­‐treated	  relative	  to	  vehicle	  treated	  control	  cells	  from	  3	  
independent	  experiments.	  G)	  CellRox	  detection	  of	  ROS	  levels	  in	  human	  CRC	  lines,	  as	  per	  (F),	  upon	  
acute	  inhibition	  of	  NUAK1.	  	  Mean	  ±	  SEM	  from	  3	  independent	  experiments	  shown;	  asterisks	  denote	  
significance	   (1-­‐tailed	  T-­‐test)	  H)	  Representative	   image	   showing	  CellRox	   staining	  of	  VAK	   spheroids	  
after	   treatment	   with	   HTH-­‐01-­‐015.	   	   I)	   quantification	   of	   spheroid	   fluorescence	   from	   (H)	   using	  
ImageJ.	  N=41	  per	  group.	  	  J)	  Apoptosis	  induced	  by	  treatment	  of	  U2OS	  (500µM)	  or	  CRC	  cells	  (1mM)	  
with	  H2O2,	  with	   and	  without	   prior	   depletion	   of	  NUAK1,	  measured	   at	   24hrs.	   	  Mean	  &	   SEM	  of	   3	  
biological	   replicates	   from	  at	   least	  2	   independent	  experiments	   for	  each	  cell	   line	  shown.	  Asterisks	  
denote	   significance	   (unpaired	   T-­‐test).	   K)	   Provision	   of	   exogenous	   antioxidant	   Trolox	   attenuates	  
HTH-­‐01-­‐015-­‐induced	   killing	   in	   human	   CRC	   lines.	   Mean	   &	   SEM	   of	   3	   independent	   experiments	  
shown.	   	  Asterisks	  denote	   significance	   (2-­‐way	  ANOVA	  &	  post-­‐hoc	  Tukey	   test).	   	  L)	   Representative	  
images	   showing	   Trolox	   rescues	   growth	   of	   Colonic	   VAHomK	   spheroids	   from	   Nuak1	   inhibition	   (3	  
days).	  Scale	  bar	  =100µm.	  Right	  panel	  shows	  quantification	  of	  spheroids	  after	  NUAK1	  inhibition	  in	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the	   presence	   and	   absence	   of	   Trolox	   (500µM).	   Mean	   and	   SEM	   of	   3	   independent	   experiments,	  
normalized	  to	  vehicle	  treated	  controls	  are	  shown.	  	  Asterisks	  denote	  significance	  (2-­‐way	  ANOVA	  &	  
post-­‐hoc	  Tukey	  test).	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Figure	  4:	  NUAK1	  promotes	  nuclear	  accumulation	  of	  NRF2	  
A)	   NRF2	   immunoblot	   of	   U2OS	   whole	   cell	   extracts	   harvested	   after	   4	   or	   8hrs	   NUAK1	   inhibition.	  
Reduced	  phospo-­‐MYPT1	  confirms	  NUAK1	   inhibition.	  The	   lower	  panel	  shows	  densitometry	  of	   the	  
NRF2	  blot	  shown.	  	  B)	  NRF2	  immunoblot	  of	  KEAP1	  depleted	  U2OS	  cells	  upon	  NUAK1	  inhibition	  for	  
8hrs.	   	   The	   lower	   panel	   shows	   densitometry	   of	   the	  NRF2	   blot	   shown.	   	   The	   right	   panel	   confirms	  
KEAP1	   depletion	  with	   2	   independent	   siRNAs.	  C)	   Immunoblots	   of	  NRF2	   protein	   levels	   in	   nuclear	  
extracts	   from	   U2OS	   cells	   after	   acute	   (30mins)	   treatment	   of	   cells	   with	   500µM	   H2O2,	   with	   and	  
without	   prior	   depletion	   of	   NUAK1	   by	   2	   distinct	   siRNAs	   (left	   &	   center	   panels),	   or	   upon	   NUAK1	  
inhibition	   by	   HTH-­‐01-­‐015	   (10µM).	   All	   blots	   (A-­‐C)	   are	   representative	   of	   at	   least	   3	   independent	  
experiments.	  D)	  Expression	  analysis	  of	  NRF2	  target	  genes	  GCLC	  and	  GCLM	  shows	  suppression	  of	  
H2O2-­‐induced	   mRNA	   levels	   upon	   depletion	   of	   NUAK1.	   Mean	   and	   SEM	   of	   3	   independent	  
experiments,	  normalized	  to	  pre-­‐peroxide	  treatment,	  are	  shown.	  Asterisks	  denote	  significance	  (2-­‐
way	  ANOVA	  &	  post-­‐hoc	  Tukey	  test).	  	  E)	  Suppression	  of	  ROS-­‐induced	  NRF2	  nuclear	  translocation	  in	  
multiple	  human	  CRC	  cell	  lines	  upon	  depletion	  of	  NUAK1.	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Figure	  5:	  NUAK1	  inhibits	  negative	  regulation	  of	  NRF2	  by	  GSK3β  
A)	   Summary	   of	   phospho-­‐proteomic	   changes	   induced	   in	   U2OS	   cells	   upon	   treatment	  with	   10µM	  
HTH-­‐01-­‐015	   for	  1hr.	   	   Left	  panel	  depicts	   the	  comparison	  of	  “forward”	   	   (X-­‐axis)	  with	  “reverse”	   (Y-­‐
axis)	   SILAC	   labeled	   cells.	   	   Phosphorylation	   sites	   in	   the	   lower	   left	   quadrant	   thus	   show	  consistent	  
reduction	   in	   levels	   while	   those	   in	   the	   upper	   right	   quadrant	   show	   consistently	   higher	  
phosphorylation	  levels	  detected	  by	  mass	  spectrometry.	  The	  previously	  validated	  NUAK1	  substrate	  
MYPT1	  was	   used	   to	   set	   a	   threshold	   for	   acceptance/rejection	   of	  modulated	   phosphor-­‐peptides.	  	  
Right	   panel	   shows	   zoom	  of	   the	   inset	   from	   left	   panel,	  with	   known	   (red)	   and	   predicted	   (orange)	  
GSK3β	  substrates	  highlighted.	  	  B)	   Immunoblots	  of	  lysates	  from	  NUAK1-­‐depleted	  or	  control	  U2OS	  
cells	   after	   treatment	   with	   H2O2	   (500µM)	   showing	   effects	   on	   AKT,	   GSK3β and	   MYPT1	  
phosphorylation.	   The	   lower	   panel	   shows	   the	   ratio	   of	   Ser9-­‐phospho-­‐/total	   GSK3β,	   measured	   by	  
Image-­‐J	   analysis	   of	   the	   presented	   immunoblots.	  C)	   Immunoblots	   of	   NUAK1-­‐depleted	   or	   control	  
SW480	   cytosolic	   fractions	   after	   treatment	  with	   H2O2	  (30	  minutes).	   	   The	   lower	   panel	   shows	   the	  
ratio	  of	  Ser9-­‐phospho-­‐/total	  GSK3β,	  measured	  by	  Image-­‐J	  analysis	  of	  the	  presented	  immunoblots.	  	  
D)	   Immunoblots	   show	   reduced	   Ser9-­‐phosphorylation	   of	   GSK3β	   in	   the	   presence	   of	   NUAK1	  
inhibitors.	   	  The	  lower	  panel	  shows	  the	  ratio	  of	  Ser9-­‐phospho-­‐/total	  GSK3β,	  measured	  by	  Image-­‐J	  
analysis	  of	  the	  presented	  immunoblots.	  	  E)	   	  Immunoblots	  show	  suppression	  of	  nuclear	  NRF2	  and	  
Ser9-­‐phosphorylation	   of	   GSK3β upon	   inhibition	   of	   NUAK1	   (5µM	   HTH-­‐01-­‐015	   for	   16hrs)	   in	   VAK	  
large	   intestine-­‐derived	  spheroids.	  Note	   that	   the	  presence	  of	  Matrigel	   likely	  blunts	   the	   impact	  of	  
treatment	  with	  exogenous	  H2O2	  (2mM	  for	  1hr).	   	  The	  lower	  panel	  shows	  quantification	  of	  nuclear	  
NRF2	   levels	   by	   Image-­‐J	   analysis.	   	  F)	   Pre-­‐treatment	   of	  NUAK1	   depleted	   SW480	   cells	  with	  GSK3β	  
inhibitors	  BIO-­‐acetoxime	  (a;	  1µM	  for	  6hrs)	  or	  CHIR99021	  (b;	  3µM	  for	  6hrs)	  restores	  ROS-­‐induced	  
NRF2	  nuclear	  translocation.	  	  All	  images	  are	  representative	  of	  at	  least	  3	  independent	  experiments.	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Figure	  6:	  Regulation	  of	  NUAK1	  by	  NRF2	  and	  ROS	  
A)	   Immunoblots	   show	  reduced	  NUAK1	  protein	  and	   reduced	  MYPT1S445-­‐phosphorylation	   in	  U2OS	  
cells	   upon	   depletion	   of	   NRF2	   using	   2	   distinct	   siRNAs.	   B)	   Alignment	   of	   a	   putative	   anti-­‐oxidant	  
response	  element	  (ARE)	   in	  the	  NUAK1	  promoter	  with	  the	  NRF2-­‐binding	  consensus	  sequence.	   	  C)	  	  
Chromatin	   IP	   of	  NRF2-­‐bound	  DNA	  probed	  with	   primer	   pairs	   flanking	   (F1/R1;	   F2/R2)	   or	   distal	   to	  
(F3/R3)	   the	   putative	   ARE	   in	   the	   NUAK1	   promoter	   (see	   diagram).	   	   The	   right	   panel	   shows	   NRF2	  
binding	  to	  the	  canonical	   target	  gene	  HMOX1	  from	  the	  same	  analysis.	   	  Mean	  &	  SEM	  of	  technical	  
replicates	  from	  1	  of	  2	  independent	  experiments	  shown.	  	  D)	  QPCR	  measurement	  of	  NUAK1	  mRNA	  
in	  U2OS	   cells	   treated	  with/without	  H2O2	   (100µM)	   for	   4hrs.	   	  Mean	  &	   SEM	  of	   3	   experiments.	   	   *	  
denotes	   significance	   (paired	  T-­‐test).	   	  E)	   Immunoblot	  of	  NUAK1	  protein	   levels	   after	   treatment	  of	  
U2OS	  cells	  (1hr)	  with	  the	  indicated	  concentrations	  of	  H2O2.	   	  F)	   Immunoblots	  of	  T211	  NUAK1	  and	  
S445	  MYPT1	  phosphorylation	  upon	  acute	  treatment	  of	  U2OS	  (left	  panels)	  or	  SW480	  (right	  panels)	  
with	  H2O2	  for	  the	  indicated	  times.	  	  G)	  Oxidation	  of	  NUAK1	  protein	  detected	  by	  Dimedone	  labeling	  
of	  U2OS	   cells	   expressing	   FLAG-­‐tagged	  NUAK1	  and	   treated	   for	  5	  minutes	  with	  500mM	  H2O2.	   	  H)	  
Identification	   of	   oxidized	   Cysteines	   in	   FLAG-­‐tagged	   NUAK1	   by	   MS	   analysis	   of	   Iodoacetamide	  
labeling	  of	  U2OS-­‐FLAG-­‐NUAK1	  cells	  treated	  with/without	  H2O2	  for	  5	  minutes.	  Lysates	  were	  labeled	  
with	  heavy	   (13C)	  or	   light	   (12C)	   Iodoacetamide,	   followed	  by	   immunoprecipitation	  of	   FLAG-­‐NUAK1.	  
Plot	  shows	  analysis	  of	  reciprocally	  labeled	  samples	  from	  2	  independent	  experiments.	  Mean	  and	  SD	  
indicated.	   	   I)	   Model	   integrating	   NUAK1	   suppression	   of	   PP1β-­‐dependent	   de-­‐phosphorylation	   of	  
GSK3β	   as	   an	   integral	   step	   in	   nuclear	   mobilization	   of	   NRF2	   in	   response	   to	   oxidative	   stress.
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Figure	  7:	  Acute	  depletion	  of	  NUAK1	  reverses	  colorectal	  tumors	  via	  increased	  ROS	  
A)	  Colonic	  tumor	  number	  per	  mouse	  (left	  panel),	  total	  tumor	  burden	  (center	  panel)	  and	  individual	  
tumor	  size	  (right	  panel),	   in	  DSS-­‐treated	  VA	  mice	  after	  7	  days	  of	  Nuak1	  depletion	  in	  the	  gut	  using	  
either	  of	  2	  doxycycline-­‐inducible	   shRNAs	   (1533,	  N=10;	  or	  612,	  N=7),	   compared	  with	  doxycycline	  
treated	  controls	  lacking	  either	  shRNA	  or	  the	  rtTA3	  allele	  (-­‐,	  N=7).	  Graphs	  depict	  Mean	  (blue	  lines)	  
and	   SEM	   (red	   bars).	   	   Red	   asterisks	   indicate	   significance,	   relative	   to	   untreated	   controls	   (1-­‐way	  
ANOVA	   &	   post-­‐hoc	   Tukey	   test).	   An	   outlier	   mouse	   in	   the	   shNuak-­‐612	   cohort	   is	   circled	   (center	  
panel)	  and	  all	   tumors	  present	  within	  the	  LI	  of	   that	  mouse	  are	   labeled	   in	  blue	   (right	  panel).	   	  The	  
outlier	  and	  corresponding	  tumors	  were	  included	  in	  the	  statistical	  analysis.	  	  Total	  tumor	  burden	  is	  
significantly	   reduce	  by	   shNUAK1-­‐612	   if	   the	  outlier	   is	  omitted.	   	  B)	  Representative	   IHC	  analysis	  of	  
proliferation	  (BrdU),	  apoptosis	  (TUNEL)	  and	  oxidative	  damage	  (nuclear	  8-­‐Oxo-­‐deoxyGuanine)	  with	  
corresponding	   ISH	   analysis	   of	   NUAK1	   mRNA	   (red	   dots)	   in	   selected	   tumors	   from	   control	   (top	  
panels)	   and	   shNUAK1-­‐1533	   mice	   treated	   for	   2	   days	   with	   doxycycline.	   	   C)	   HALO	   automated	  
quantification	   of	   BrdU,	   TUNEL	   &	   8-­‐Oxo-­‐Guanine	   IHC	   in	   individual	   tumors	   from	   shNUAK1	  
expressing	  (N=6)	  or	  control	  (N=6)	  mice,	  as	  per	  (B).	  Mean	  (blue	  bars)	  and	  SEM	  (red	  bars)	  indicated.	  	  
Red	  asterisks	   indicate	  significance	  (Mann	  Whitney	  Test).	   	  D)	  Tumor	  number,	   total	   tumor	  burden	  
and	  individual	  tumor	  size	  in	  DSS-­‐treated	  VA	  mice	  after	  7	  days	  of	  Nuak1	  depletion	  in	  the	  gut	  using	  
shNuak-­‐1533,	   in	   mice	   given	   N-­‐Acetyl-­‐Cysteine	   (NAC,	   N=8)	   compared	   with	   no	   exogenous	   anti-­‐
oxidant	  (nt).	   	  Note	  that	  the	  NAC-­‐untreated	  data	  are	  the	  same	  used	   in	  (A).	  Red	  asterisks	   indicate	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Supplementary	  Materials	  &	  Methods	  
Mice	  &	  procedures	  
The	  Villin-­‐CreERT2	   (51);	   Floxed	  Apc	   (52);	   LSL-­‐KRasG12D	   (53),	   floxed	  Nuak1	   (11)	  &	  Rosa26-­‐CAAGS-­‐rtTA3	   (54)	  
allelic	   mice	   were	   described	   previously.	   Mice	   bearing	   the	   doxycycline-­‐inducible	   shRNA	   alleles	   targeting	  
Nuak1	   were	   generated	   by	   Mirimus	   Inc.,	   as	   described	   previously	   (55):	   Briefly,	   shRNA	   candidates	   were	  
selected	  using	   the	  sensor	  assay	   (56).	  Two	  shRNAs	  were	  chosen	   that	   scored	  >5	  and	  produced	  knockdown	  
>90%.	   The	   selected	   shRNA	   sequences	  were	   subsequently	   cloned	   in	   the	  miR-­‐E	   backbone	   (57)	   within	   the	  
3’UTR	  of	   a	   turboGFP	   cDNA	  downstream	  of	   a	   TRE	   in	   the	  Col1a1	  TtGM	  vector	   and	   targeted	   to	   the	  Col1a1	  
locus	  using	   standard	  protocols	   (54).	   Targeted	  ES	   cells	  were	   injected	  using	  blastocyst	   injection	   technique.	  
Resulting	  shRNA	  mice	  were	  of	  mixed	  C57BL/6	  ×	  129/SV	  background.	  	  
For	  tumor	  enumeration,	  small	  intestines	  and	  colons	  were	  flushed	  with	  PBS,	  mounted	  ‘en	  face’	  and	  
fixed	   overnight	   in	   formalin.	   Tumor	   area	   was	   measured	   as	   width	   by	   length,	   omitting	   depth	   as	  
negligible/immeasurable	   in	   many	   instances.	   For	   histological	   examination,	   fixed	   tissue	   was	   then	   rolled	  
(‘swiss	  roll	  method’)	  and	  embedded	  in	  paraffin	  for	  sectioning,	  followed	  by	  standard	  staining	  in	  hematoxylin	  
and	   eosin	   (H&E).	   Additionally,	   prior	   to	   fixation	   and	   immediately	   upon	   harvest,	   a	   small	   number	   of	  
representative	   tumors	   and	   adjacent	   normal	   tissue	  were	   dissected	   and	   flash-­‐frozen	   for	   RNA	   analysis.	   For	  
immunohistochemistry,	  FFPE	  tissue	  sections	  were	  deparaffinized	  in	  3	  changes	  of	  xylene	  and	  rehydrated	  in	  
graded	  ethanol	  solutions.	  Antigen	  retrieval	  was	  performed	  by	  microwaving	  in	  10mM	  Sodium	  Citrate,	  pH6.0.	  	  
Endogenous	  peroxidases	  were	  quenched	  in	  3%	  H2O2	  and	  non-­‐specific	  binding	  was	  blocked	  with	  1	  or	  3%	  BSA	  
solution.	  	  The	  following	  antibodies	  were	  used:	  	  Ki67	  (Thermo	  Fisher,	  RM-­‐9106-­‐S0);	  Cleaved	  Caspase	  3	  (Cell	  
Signaling,	   9661);	   Lysozyme	   (Dako,	   A099);	   BrdU	   (Beckton	   Dickenson,	   BD347580);	   8-­‐Oxo-­‐dG	   (Abcam,	  
AB48508).	  Goblet	   cells	  were	   stained	  with	  Periodic	  acid	  Schiff	   (PAS).	  TUNEL	  staining	  was	  performed	  using	  
ApopTag	  peroxidase	  kits	  (Millipore).	  For	  quantification	  of	  IHC,	  3-­‐5	  20X	  fields	  were	  scored	  on	  representative	  
sections	  from	  at	  least	  3	  mice	  of	  each	  genotype.	  	  In	  situ	  hybridization	  (RNA-­‐Scope)	  was	  performed	  according	  
to	  the	  manufacturers	  directions	  (Advanced	  Cell	  Diagnostics;	  ACD):	  4μm	  FFPE	  tissue	  sections	  were	  baked	  at	  
60oC	   for	   1hr,	   then	   de-­‐paraffinized	   and	   rehydrated.	   	   Endogenous	   peroxidases	   were	   blocked	   in	   H2O2,	  
followed	  by	  antigen	  retrieval	  (100oC	  for	  8	  min.)	  and	  protease	  digestion	  (H2O2	  &	  Protease	  Plus	  kit,	  ACD).	  	  For	  
in-­‐situ	  hybridization,	  sections	  were	  hybridized	  with	  ACD-­‐designed	  probes	  for	  Nuak1	  (434281),	  positive	  ctrl	  
PP1β	  (313911)	  or	  negative	  ctrl	  DapB	  (322330)	  for	  2hrs	  at	  40oC.	  Probe	  detection	  was	  performed	  using	  RNA-­‐
Scope	  kit	  reagents	  (ACD	  322310)	  and	  counterstained	  with	  Hematoxylin.	  
	  
Cell	  culture	  &	  analysis	  
U2OS,	  HCT-­‐116;	  SW620;	  LS174T	  and	  SW480	  cells	  were	  obtained	  from	  the	  ATCC	  and	  maintained	  in	  DMEM	  
(25mM	  Glucose)	  with	  Penn/Strep	  and	  10%	  FBS.	   	  All	   cell	   lines	  were	  validated	  using	  an	  approved	   in-­‐house	  
validation	  service	  (CRUK-­‐BICR)	  and	  tested	  periodically	  for	  mycoplasma.	  Primary	  mouse	  embryo	  fibroblasts	  
(MEFs)	   were	   generated	   as	   previously	   described	   (58)	   by	   interbreeding	   heterozygous	   floxed	  Nuak1	   mice,	  
generating	  homozygous	  Nuak1FL/FL	  and	  Nuak1+/+	  MEFs,	  and	  maintained	  as	  above.	   	  To	  delete	  floxed	  Nuak1,	  
MEFs	  were	   infected	  overnight	  with	  300pfu/cell	  Adeno-­‐CRE	  (Uni.	   Iowa).	  Alternatively,	  MEFs	  were	   infected	  
with	   retrovirus	   expressing	   CreERT2,	   selected	   on	   Puromycin	   for	   48hrs,	   and	   CreERT2	   was	   subsequently	  
activated	   by	   treatment	   with	   100nM	   4-­‐OHT.	   Cells	   in	   log	   phase	   growth	   were	   treated	   with	   the	   indicated	  
concentrations	  of	  Nuak1	  inhibitors	  (HTH-­‐01-­‐015	  and	  WZ4003).	  	  Where	  indicated,	  cells	  were	  pre-­‐incubated	  
with	  500µM	  of	  Trolox	  for	  8hrs	  prior	  to	  treatment	  with	  Nuak1	  inhibitor.	  	  Equivalent	  volumes	  of	  DMSO	  were	  
used	  as	  vehicle	  controls.	  	  Reactive	  Oxygen	  species	  were	  measured	  after	  8hrs	  Nuak1	  inhibition	  using	  CellROX	  
Deep	   Red	   or	   MitosOX	   reagents	   (Thermo)	   according	   to	   the	   manufacturers	   directions,	   followed	   by	   FACS	  
analysis.	   For	   cell	   death	   measurements,	   cells	   were	   trypsinized,	   quenched	   with	   1%	   BSA	   followed	   by	  
replacement	  of	  original	  supernatant,	  and	  centrifuged	  at	  300	  x	  G	  for	  5mins;	  200ul	  of	  Annexin	  binding	  buffer	  
(10mM	  HEPES	   (PH	  7.40,	  140mM	  NaCl,	  2.5mM	  CaCl2)	  and	  2µl	  of	  Annexin	  V-­‐APC	   (Biolegend	  640920)	  were	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added	  to	  the	  pellet	  and	  incubated	  for	  15mins.	  Propidium	  iodide	  (PI,	  10µg/ml)	  was	  added	  immediately	  prior	  
to	  FACS	  analysis.	  Alternatively,	   cells	  were	   imaged	  by	   Incucyte	   (Essen	  Bio)	   time-­‐lapse	  video-­‐microscopy	   in	  
the	   presence	   of	   Sytox	   green	   reagent	   (Thermo	   Fisher).	   For	   immunoblotting,	   whole	   cell	   lysates	   were	  
prepared	   in	  RIPA	  buffer	   (150mM	  NaCl,	  50mM	  Tris,	  pH	  7.5,	  1%	  NP-­‐40,	  0.5%	  sodium	  deoxycholic	   acid,	  1%	  
SDS,	  plus	  complete	  protease	  and	  phosphatase	  inhibitor	  cocktail)	  followed	  by	  sonication	  (40%	  Amp	  for	  5s).	  	  
Cytoplasmic	  and	  Nuclear	  fractions	  were	  prepared	  in	  low	  salt	  buffer	  (20mM	  KCL,	  10mM	  HEPES,	  pH	  7.5,	  1mM	  
MgCl2,	  1mM	  CaCl2,	  0.1%	  Triton	  X-­‐100)	  followed	  by	  centrifugation	  at	  3300	  rpm	  for	  3min.	  	  NUAK1	  (CST	  4458,	  
1:750);	   NUAK2	   (Hs:	   MRC,	   S225B,	   Mm:	   CST	   4100);	   NRF2	   (Novus	   NB100-­‐80011,	   1:1000);	   pMYPT1	   (MRC	  
S5087,	   1:400);	   total	  MYPT	   (BD	   612164,	   1:1000);	   β-­‐Actin	   (Sigma	   A5441,	   1:5000);	   Lamin	   A/C	   (Santa	   Cruz,	  
6215),	  Keap1	  (Santa	  Cruz,	  15246);	  phosphor	  AMPK	  substrate	  (CST	  5759)	  were	  used	  as	  primary	  antibodies.	  
Secondary	  horseradish	  peroxidase	  conjugated	  antibodies	  (α-­‐mouse	  IgG	  NA931V;	  α-­‐rabbit	  NA934V,	  both	  GE	  
Healthcare;	  α-­‐goat	   IgG,	   Vector	   Labs	   PI-­‐9500)	   were	   detected	   by	   chemiluminescence	   (Pierce	   ECL	   western	  
blotting	  substrate	  32106).	  For	  immuno-­‐precipitations	  (IPs),	  2.5x106	  cells	  were	  seeded	  per	  15cm	  dish.	  Next	  
day,	  5ug	  of	  NRF2-­‐Flag	  or	  empty	  vector	  was	  transfected	  using	  Lipofectamine	  3000	  reagent	   (1:1.8	  ratio	   for	  
Lipofectamine,	  1:2	  for	  p3000	  reagent).	  48hrs	  post	  transfection,	  cells	  were	  trypsinized	  and	  5x106	  cells	  were	  
seeded	  per	  15cm	  dish.	  Cells	  were	  treated	  with	  10µM	  HTH	  or	  DMSO	  for	  8hrs,	  then	  washed	  with	  ice	  cold	  PBS	  
and	  scraped	  in	  400µl	  of	  NP-­‐40	  lysis	  buffer	  (150mM	  NaCl,	  50mM	  Tris	  Ph7.5,	  1mM	  EDTA,	  1mM	  EGTA,	  1%	  NP-­‐
40,	  plus	  complete	  protease	  and	  phosphatase	  inhibitor	  cocktail).	   	  Lysates	  were	  incubated	  on	  ice	  for	  10min	  
and	  centrifuged	  at	  12k	  rpm	  for	  10min	  and	  the	  supernatant	  was	  used	  for	  IP.	  1.5mg	  of	  total	  protein	  was	  used	  
per	   condition.	   Lysates	   were	   incubated	   with	   Flag-­‐M2	   resin	   (20µl	   /µg	   of	   protein)	   overnight.	   Beads	   were	  
pelleted	  at	  3000rpm/5	  minutes	  and	  washed	  3X	  with	  the	  lysis	  buffer	  (3000	  rpm/5mins/4oC).	  IP’ed	  proteins	  
were	  eluted	   in	  60µl	  of	  1x	  Laemlli	  buffer.	   	  The	  following	  siRNAs	  were	  used	  at	  20nM,	  except	  where	  noted:	  
NUAK1	  D-­‐004931-­‐01-­‐002	   (40nM,	  Dharmacon)	   SI00108402	   (10nM,	  Qiagen);	   NUAK2	   SI02660224	   (Qiagen);	  
NRF2	   SI03246950,	   SI04223009	   (Qiagen);	   KEAP1	   S104155424,	   S103246439	   (Qiagen);	   	   MYC	   SI03101847	  
(Qiagen);	   PTEN	   SI00301504,	   SI03048178	   (Qiagen).	   For	   Dimedone	   detection	   of	   Cysteine	   oxidation,	   USOS	  
cells	   transiently	  overexpressing	  FLAG-­‐tagged	  NUAK1	  were	   treated	  with	  H2O2	   for	  5	  minutes,	   then	   lysed	   in	  
RIPA	  buffer	  containing	  1mM	  Dimedone	  (Sigma,	  D153303)	  followed	  by	  α-­‐FLAG	  IP.	  Dimedone	  incorporation	  
was	   detected	   using	  α-­‐Dimedone	   antibody	   (Millipore,	   07-­‐2139).	   Iodo-­‐acetamide	   labeling	   was	   performed	  
similarly	   by	   addition	   of	   55mM	   labeled	   (13C2D2H2INO;	   Sigma-­‐Aldrich/	   Merck	   KGaA,	   721328)	  or	   unlabeled	  
(C2H4INO;	  Sigma-­‐Aldrich/	  Merck	  KGaA,	  I6125)	  iodoacetamide	  in	  RIPA	  buffer,	  followed	  by	  anti-­‐FLAG	  IP.	  	  IPs	  
were	  washed	  twice	  in	  lysis	  buffer,	  followed	  by	  H2O,	  prior	  to	  combining	  H2O2	  treated	  and	  untreated	  samples	  
for	  MS	  analysis	  (see	  below).	  Label	  incorporation	  was	  normalized	  to	  the	  level	  of	  IP’ed	  NUAK1,	  measured	  by	  
immunoblotting	  of	  10%	  of	  each	  IP.	  
	  
Gene	  expression	  analysis	  	  
U2OS	  cells	  were	  depleted	  of	  Nuak1	  by	  shRNA-­‐4977	  as	  previously	  described	  (9)	  and	  selected	  on	  puromycin	  
for	   48hrs.	   Control	   cells	   were	   similarly	   selected	   after	   infection	   with	   non-­‐targeting	   shRNA	   expressing	  
retrovirus.	  	  SW480	  and	  HCT116	  cells	  were	  depleted	  of	  NRF2	  or	  NUAK1	  by	  siRNA.	  24hrs	  after	  re-­‐seeding	  in	  
the	   absence	   of	   selection,	   total	   RNA	   was	   isolated	   using	   the	   RNEasy	   Mini	   Kit	   (Qiagen)	   according	   to	  
manufacturer’s	  instructions	  and	  DNA	  was	  depleted	  with	  the	  RNase-­‐Free	  DNase	  Set	  (Qiagen).	  RNA-­‐integrity	  
was	  checked	  using	   the	  RNA	  ScreenTape	  assay	   (Agilent	  Technologies)	  and	  cDNA	  was	  synthesized	  with	   the	  
TruSeq	   Stranded	   mRNA	   Library	   Prep	   Kit	   (Illumina).	   Following	   library	   quantification	   (D1000	   ScreenTape,	  
Agilent	  Technologies),	   libraries	  were	  standardized	   to	  10nM,	  denatured,	  diluted	   to	  10pM	  and	  analyzed	  by	  
paired-­‐end	  sequencing	  using	  an	  Illumina	  NextSeq500	  platform.	  RNA-­‐Sequencing	  reads	  were	  aligned	  to	  the	  
GRCh38	   version	   of	   the	   human	   genome	   or	   the	   GRCm38	   version	   of	   the	   murine	   genome	   and	   differential	  
expression	  determined	  using	  DESeq2	   (59).	   	   Pathway	  modulation	  analysis	  was	  performed	  using	  Metacore	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GeneGO	  (Thompson	  Reuters).	  For	  analysis	  of	  individual	  genes,	  RNA	  was	  isolated	  using	  TRIZOL	  (Invitrogen)	  
as	  per	  manufacturer’s	  directions.	  cDNA	  was	  synthesized	  using	  Quantitect	  reverse	  transcription	  kit	  (Qiagen	  
205313)	  followed	  by	  real	  time	  PCR	  using	  SYBR	  Green	  method	  (VWR	  QUNT95072).	  The	  following	  primer	  sets	  
were	  used	  to	  detect	  indicated	  mRNA	  transcripts:	  
Human	  	  
GCLC	  F:	  5’atgccatgggatttggaat;	  R:	  5’gatcataaaggtatctggcctca	  
GCLM	  F:	  5’gttggaacagctgtatcagtgg;	  R:	  5’gttggaacagctgtatcagtgg	  
GSHR	  F:	  5’atgatcagcaccaactgcac;	  R:	  5’cttccaagcccgacaaagt	  
MGST	  F:	  5’accacaccattgcatatttgac;	  R:	  5’gccatggaaagagtaactcca	  
TXN	  F:	  5’ttacagccgctcgtcaga;	  R:	  5’ggcttcctgaaaagcagtctt	  
β-­‐ACTIN	  F,	  5’ccaaccgcgagaagatga;	  R:	  5’ccagaggcgtacagggatag	  
NUAK1	  F:	  5’acatgatctcaatctctcgtctg;	  R:	  5’acctacggcaaagtcaagc	  
Mouse	  
Gclc	  L:	  5’agatgatagaacacgggaggag;	  R:	  5’tgatcctaaagcgattgttcttc	  
Gclm	  L:	  5’tgactcacaatgacccgaaa;	  R:	  5’tcaatgtcagggatgctttct	  
Gshr	  L:	  5’ctatgacaacatccctactgtggt;	  R:	  5’cccatacttatgaacagcttcgt	  
Mgst	  L:	  5’gcccttctccctggattc;	  R:	  5’ggccatcaacacctcattgt	  
Txn	  L:	  5’tgaagctgatcgagagcaag;	  R:	  5’agaagtccaccacgacaagc	  
B2m	  F:	  5’agccgaacatactgaactgctacg;	  R:	  5’cggccatactgtcatgcttaactc	  
Nuak1	  F:	  5’gagcccacacaaccctca;	  R:	  5’tctgcgatcgggattcac	  
A	  human	  CRC	  tissue	  micro-­‐array	  comprising	  650	  tissue	  cores	  was	  stained	  for	  NUAK1	  mRNA	  expression	  by	  
RNA-­‐Scope	  (as	  described	  above)	  and	  scored	  blindly	  using	  Halo	  image	  analysis	  software	  (Indicalab).	  Omitting	  
47	   results	   that	   failed	   quality	   control	   (undetectable	   PP1β	   expression),	   results	  were	   subdivided	   into	   equal	  
quartiles	  from	  low	  to	  high	  NUAK1	  expression	  and	  P	  values	  were	  determined	  by	  Chi-­‐Square	  test.	  
	  
Proteomic	  analysis	  
SILAC	  labeling:	  U2OS	  cells	  were	  cultured	  in	  light	  (12C614N4	  L-­‐arginine	  and	  12C614N2	  L-­‐lysine,	  Sigma)	  and	  heavy	  
(13C615N4	  L-­‐arginine	  and	  13C615N2	  L-­‐lysine,	  Cambridge	  Isotope	  Laboratories)	  SILAC	  medium	  (SILAC	  DMEM,	  Life	  
Technologies)	  supplemented	  with	  10	  KDa	  dialysed	  serum	  (Sigma)	  until	  full	  labeling	  (>98%)	  of	  the	  proteome	  
was	  reached.	  	  For	  “forward	  analysis”	  heavy	  labeled	  cells	  were	  treated	  for	  1hr	  with	  10	  μM	  HTH-­‐01-­‐015,	  and	  
light	  labeled	  cells	  were	  vehicle	  treated.	  Cells	  were	  then	  harvested	  and	  lysates	  mixed	  in	  equal	  amounts.	  For	  
the	   reverse	   replicate	   experiment,	   light	   labeled	   cells	   were	   treated	   for	   1hr	   with	   10	   μM	   HTH-­‐01-­‐015,	   and	  
heavy	   labeled	  cells	  were	  vehicle	   treated.	   	   Sample	  Preparation:	   	  1.5	  mg	  of	  each	  cell	   lysate	   from	   light	  and	  
heavy	  SILAC	  labeled	  cells	  were	  mixed	  1:1,	  light	  Ctl	  :	  heavy	  HTH	  in	  the	  forward	  experiment	  and	  light	  HTH	  and	  
heavy	  Ctl	  in	  the	  reverse	  experiment.	  Proteins	  were	  precipitated	  overnight	  at	  -­‐20	  C	  in	  acetone,	  re-­‐dissolved	  
in	  8M	  Urea,	  0.1	  M	  TrisHCl	  pH	  8.5	  buffer	  with	  phosphatase	   inhibitors	   (Halt	  phosphatase	  cocktail,	   Thermo	  
Scientific)	   and	   digested	  with	   Lys-­‐C	   (Alpha	   Laboratories)	   and	   Trypsin	   (Promega)	   using	   Filter-­‐Aided	   Sample	  
Preparation	   (FASP)	   (60).	   To	   remove	   salts,	   peptides	  were	   loaded	   onto	   C18	   Sep-­‐Pak	   column	   (Waters)	   and	  
eluted	  with	   increasing	   concentration	   of	   acetonitrile	   (ACN,	   10%,	   15%,	   20%,	   25%,	   30%,	   40%,	   60%)	   in	   01%	  
trifluoroacetic	  acid.	  ACN	  was	  removed	  using	  a	  speed	  vacuum	  centrifuge	  and	  peptides	  were	  resuspended	  in	  
MOPS	  50	  mM,	  sodium	  phosphate	  10	  mM,	  sodium	  chloride	  50	  mM	  pH	  7.2.	  Fresh	  ACN	  was	  added	  to	  30%	  
final	   concentration	   and	   TFA	   to	   pH	   down	   to	   2.5.	   The	   enrichment	   for	   phosphorylated	   peptides	   was	  
performed	  incubating	  the	  peptide	  solution	  with	  TiO2	  beads,	  5:1,	  peptide:TiO2,	  as	  previously	  described	  (60).	  
Four	  subsequent	  incubations	  with	  TiO2	  were	  performed.	  Peptides	  were	  eluted	  from	  the	  TiO2	  beads	  using	  a	  
solution	  15%	  ammonium	  hydroxide	  40%	  ACN	  and	   loaded	  onto	  a	  C18	  StageTip	  (62).	  Peptides	  were	  eluted	  
from	  StageTip	  with	  80%	  ACN,	  speed	  vac	  and	  resuspended	  in	  1%	  ACN,	  0.05%	  TFA	  for	  MS	  analysis.	  Peptides	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recovered	  from	  the	  four	  incubations	  were	  run	  separately	  at	  the	  MS.	  	  MS	  analysis:	  	  Digested	  peptides	  were	  
injected	  on	  an	  EASY-­‐nLC	  system	  coupled	  on	  line	  to	  a	  LTQ-­‐Orbitrap	  Elite	  via	  a	  nanoelectrospray	  ion	  source	  
(Thermo	   Fisher	   Scientific).	   Peptides	   were	   separated	   using	   a	   20	   cm	   fused	   silica	   emitter	   (New	   Objective)	  
packed	  in	  house	  with	  reversed-­‐phase	  Reprosil	  Pur	  Basic	  1.9	  µm	  (Dr.	  Maisch	  GmbH)	  and	  eluted	  with	  a	  flow	  
of	   200	   nl/min	   from	   5%	   to	   25%	   of	   buffer	   containing	   80%	   ACN	   in	   0.5%	   acetic	   acid,	   in	   a	   190	   min	   linear	  
gradient.	  The	  top	  ten	  most	  intense	  peaks	  in	  the	  full	  MS	  were	  isolated	  for	  fragmentation	  with	  high	  collision	  
energy	   dissociation.	   MS	   data	   were	   acquired	   using	   the	   XCalibur	   software	   (Thermo	   Fisher	   Scientific)	   and	  
.RAW	  files	  processed	  with	  the	  MaxQuant	  computational	  platform	  (63)	  version	  1.5.0.36	  and	  searched	  with	  
the	   Andromeda	   search	   engine	   (64)	   against	   the	   human	   UniProt	   database	   (65)	   (release-­‐2012	   01,	   88,847	  
entries).	  MaxQuant	  was	  run	  with	  the	  following	  settings:	  To	  search	  the	  parent	  mass	  and	  fragment	  ions	  we	  
required	  a	  mass	  deviation	  of	  4.5	  ppm	  and	  20	  ppm.	  The	  minimum	  peptide	   length	  was	  7	  amino	  acids	  and	  
maximum	   of	   two	   missed	   cleavages	   and	   strict	   specificity	   for	   trypsin	   cleavage	   were	   required.	  
Carbamidomethylation	   (Cys)	   was	   set	   as	   fixed	   modification,	   and	   oxidation	   (Met),	   N-­‐acetylation	   and	  
phosphoSTY	  as	  variable	  modifications.	  For	  peptide	  and	  phosphorylation	  site	  identification,	  a	  false	  discovery	  
rate	  (FDR)	  of	  1%	  was	  required.	  The	  re-­‐quantification	  and	  match	  between	  runs	  features	  were	  enabled	  and	  
the	   relative	   quantification	   of	   the	   peptides	   against	   their	   SILAC-­‐labeled	   counterparts	   was	   performed	   by	  
MaxQuant.	   For	   phosphorylation	   sites	   to	   be	   quantified,	   we	   required	   at	   least	   two	   ratio	   counts.	   The	  
MaxQuant	   output	   file	   Phospho	   (STY)Sites	  was	   analyzed	  with	   the	   Perseus	   software	   (66),	   the	   reverse	   and	  
contaminant	  hits	  were	  excluded	  and	  only	  class	  I	  phosphorylation	  sites	  (localization	  probability	  =	  probability	  
that	   the	  phosphorylation	  site	  has	  been	  accurately	   localized	  >	  0.75	  and	  score	  difference	  >	  5)	  used	   for	   the	  
analysis.	  	  Raw	  MS	  data	  is	  available	  via	  the	  PRIDE	  repository	  under	  accession	  number	  PXD008229.	  	  Cysteine	  
oxidation:	   tryptic	  peptides	  were	  separated	  by	  nanoscale	  C18	  reverse-­‐phase	   liquid	  chromatography	  on	  an	  
EASY-­‐nLC	   II	   1200	   (Thermo	   Scientific)	   coupled	   online	   to	   a	   Q-­‐Exactive	   HF	   mass	   spectrometer	   (Thermo	  
Scientific)	   and	  data	   acquired	  using	   the	  XCalibur	   software	   (Thermo	  Fisher	   Scientific).	   The	   .RAW	   files	  were	  
processed	   with	   the	   MaxQuant	   computational	   platform	   version	   1.6.0.16	   as	   described	   above,	   but	   with	  
Cysteine	   carbamidomethyl	   Heavy	   and	   Light	   as	   variable	   modifications.	   The	   Oxidation	   (M)Sites.txt	   was	  
analyzed	  with	  the	  Perseus	  software.	  
	  
Kinase	  Assays	  
GST-­‐tagged	   full	   length	   human	   NUAK1	   (product	   number	   02-­‐126)	   was	   purchased	   from	   Carna	   Biosciences,	  
Japan.	   Kinase	   assays	   were	   performed	   using	   an	   IMAP	   fluorescence	   polarization	   assay	   format	   (Molecular	  
Devices	   Inc.).	   a	   titration	   of	   kinase	   from	   470nM	   down	   to	   45nM	   was	   incubated	   for	   60	   min	   at	   room	  
temperature	   with	   100	   nM	   5Fam-­‐LKKQLSTLYL,	   NRF1-­‐derived	   peptide	   or	   5Fam-­‐VSRSGLYRSPSMPENLNRPR,	  
CDC25C-­‐	  derived	  peptide	  (synthesized	  by	  Alta	  Biosciences,	  University	  of	  Birmingham	  UK)	  in	  the	  presence	  of	  
50	  μM	  ATP	  and	  50	  mM	  MgCl2	  in	  20	  mM	  HEPES	  buffer	  (pH	  7.5)	  containing	  0.01%	  Brij-­‐35).	  Reactions	  were	  
stopped	   by	   adding	   2	   assay	   volumes	   of	   	   0.25%	   (v/v)	   IMAP	   progressive	   binding	   reagent	   in	   1x	   progressive	  
binding	  buffer	  A	   for	   the	  NRF1	  peptide	  or	   0.16%	   (v/v)	   IMAP	  progressive	  binding	   reagent	   in	   85:15%	   IMAP	  
progressive	  binding	  buffer	  A:	  Buffer	  B	   for	   the	  CDC25C	  peptide.	  After	  60	  min	   incubation	   to	  allow	  binding	  
reagent	   to	   bind	   phosphorylated	   peptide,	   fluorescence	   polarization	   was	   measured	   on	   a	   Tecan	   Infinite	  
M1000	   Pro	   plate	   reader	   at	   excitation	   (470	   nm)	   and	   emission	   (530	   nm)	   wavelengths.	   Net	   fluorescence	  
polarization	  values	  were	  calculated	  by	  subtractions	  of	  the	  control	  samples	  with	  no	  ATP.	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Figure	  S1:	  NUAK1	  is	  associated	  with	  tumor	  progression	  and	  reduced	  OS	  in	  human	  CRC.	  	  Pertains	  
to	  Figure	  1.	  
A)	   Representative	   examples	   of	  NUAK1	   levels	   in	   human	   CRC,	   detected	   by	   RNA-­‐Scope	   ISH	   (black	  
dots,	   highlighted	   in	   Q1	   and	   Q2	   by	   arrowheads)	   counterstained	   with	   hematoxylin.	   	   Scale	   bar	  
=10µm.	   	  B)	  Summary	  of	  NUAK1	  mRNA	  detection	   in	  a	  human	  CRC	  TMA.	   	  Data	  were	  divided	   into	  
equal	   quartiles	   from	   lowest	   (Q1)	   to	   highest	   (Q4)	   expression	   and	   graphed	   by	   Dukes’	   stage.	   	   Chi	  
Square	   test	   P	   value	   shown.	   	   C)	   Box	   &	   whisker	   plots	   of	   NUAK1	   mRNA	   levels	   in	   human	   CRC	  
separated	  by	  risk	  group.	  	  Blue	  =	  low	  risk,	  Red	  =	  high	  risk.	  	  T-­‐test	  P	  value	  shown.	  	  D)	  Overall	  survival	  
of	  human	  CRC	  patients	  separated	  by	  high	  versus	  low	  NUAK1	  expression.	  	  Logrank	  P	  value,	  hazard	  
ratio	   (HR)	  and	  95%	  confidence	   interval	   (CI)	   shown.	   	   (C	  &	  D)	  Data	  mined	   from	   Jorissen	  et	  al	  and	  
analyzed	  via	  Metabase	  SurvExpresss.	  	  E)	  Box	  &	  whisker	  plots	  of	  NUAK1	  mRNA	  levels	  in	  human	  CRC	  
separated	  by	  risk	  group.	  	  Blue	  =	  low	  risk,	  Red	  =	  high	  risk.	  	  T-­‐test	  P	  value	  shown.	  	  F)	  Overall	  survival	  
of	  human	  CRC	  patients	  separated	  by	  high	  versus	  low	  NUAK1	  expression.	  	  Logrank	  P	  value,	  hazard	  
ratio	   (HR)	   and	   95%	   confidence	   interval	   (CI)	   shown.	   (E	   &	   F)	   Data	   mined	   from	   Smith	   et	   al	   and	  
analyzed	   via	   Metabase	   SurvExpresss.	   G)	   Analysis	   of	   genomic	   alteration	   and	   mRNA	  
over/underexpression	  of	  NUAK1	   and	  NUAK2	   in	   the	   TCGA	   cohort	   of	   Colorectal	  Adenocarcinoma,	  
accessed	   via	   cBioportal.	   H)	   	   Immunoblots	   show	   relative	   expression	  of	  NUAK1,	  NUAK2	  and	  MYC	  
across	   the	   cell	   lines	   used	   in	   this	   study.	   	   Lysates	   from	   3x106	   cells	   per	   cell	   line	  were	   analyzed.	   I)	  
Growth	  curves	  of	  CRC	  cell	   lines	  treated	  with	  5µM	  HTH-­‐01-­‐015,	  measured	  by	  Incucyte	  time-­‐lapse	  
video	  microscopy.	   	  Mean	   &	   SD	   of	   4	   technical	   replicates	   shown.	   	   Asterisks	   indicate	   significance	  
(Unpaired	  T-­‐test).	   J)	  Growth	   curves	  of	  CRC	   cell	   lines	  upon	   siRNA-­‐mediated	  depletion	  of	  NUAK1,	  
counted	  by	  CASY	  cytometry.	  Mean	  &	  SE	  of	  3	  technical	  replicates	  from	  1	  of	  3	  experiments	  shown.	  	  
Asterisks	   indicate	   significance	   (Unpaired	   T-­‐test).	   	   K)	   Growth	   curves	   (Incucyte)	   of	   CRC	   cell	   lines	  
upon	   depletion	   of	   NUAK1	   using	   a	   second	   siRNA	   distinct	   from	   (J).	   	   Mean	   &	   SE	   of	   3	   technical	  
replicates	   from	   1	   of	   3	   independent	   experiments	   shown.	   L)	   Immunblots	   of	   NUAK1,	   NUAK2	   and	  
AMPKα1/α2	   expression	  upon	  depletion	  of	  NUAK1	   in	   CRC	   cell	   lines	   using	   2	   independent	   siRNAs	  
(from	   J	  &	  K).	  M)	  Apoptosis	  measured	   in	  human	  CRC	   lines	   after	   48hrs	  of	   combined	   inhibition	  of	  
NUAK1	   and	   NUAK2	   with	   the	   indicated	   concentrations	   of	   WZ4003.	   Red	   bars	   indicate	  
AnnexinV/Propidium	   Iodide	   (AV/PI)	   double	   positive	   cells;	   black	   bars	   indicate	   AnnexinV	   positive	  
cells.	  Mean	   and	   SEM	   of	   3	   independent	   experiments	   shown;	   asterisks	   show	   significance	   (1-­‐way	  
ANOVA	  &	  post-­‐hoc	  Tukey	  test,	  relative	  to	  vehicle	  controls	  (-­‐)).	  N)	  Phospho-­‐MYPTS445	  immunoblots	  
after	  8hr	  treatment	  with	  WZ4003	  in	  the	  indicated	  cell	  lines.	  	  O)	  Apoptosis	  induced	  in	  MEFs	  48hrs	  
after	  treatment	  with	  10µM	  HTH-­‐01-­‐015	  or	  WZ4003.	  Red	  bars	  indicate	  AnnexinV/Propidium	  Iodide	  
Port	  et	  al.	  
	  
(AV/PI)	   double	   positive	   cells;	   black	   bars	   indicate	   AnnexinV	   positive	   cells.	   Mean	   and	   SEM	   of	   3	  
independent	   experiments	   shown;	   asterisks	   show	   significance	   (1-­‐way	   ANOVA	   &	   post-­‐hoc	   Tukey	  
test,	  relative	  to	  vehicle	  controls	  (-­‐)).	  Ns	  =	  not	  significantly	  increased	  relative	  to	  untreated	  controls.	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Figure	  S2:	   Inefficient	  deletion	  of	  NUAK1	   in	   the	  small	   intestine	  and	  selective	  pressure	  to	  retain	  
NUAK1	  in	  large	  intestine	  tumours.	  Pertains	  to	  Figure	  2.	  
A)	  Schematic	  of	  alleles	  used	  to	  generate	  VAK	  and	  VAKN	  mice.	  	  CreER	  was	  transiently	  activated	  by	  a	  
single	   injection	   of	   Tamoxifen	   to	   initiate	   allele	   recombination.	   	   Over	   time,	   loss	   of	   the	   wild-­‐type	  
(non-­‐floxed)	   Apc	   allele	   allows	   sporadic	   tumor	   development	   in	   the	   gut.	   	   B)	   Number	   of	   small	  
intestine	  (SI)	  tumors	  per	  mouse	  in	  VAK	  (N=12)	  and	  VAKN	  (N=16)	  mice,	  harvested	  at	  end-­‐point.	  	  C)	  
Total	  SI	  tumor	  burden	  in	  mice	  of	  the	  indicated	  genotypes.	   	  D)	  Kaplan	  Mayer	  survival	  plot	  of	  VAK	  
(N=14)	   and	   VAKN	   (N=22)	   mice,	   measured	   from	   day	   of	   Tamoxifen	   injection.	   P	   value	   shown	   for	  
Logrank	   Test.	  E)	  Nuak1	  mRNA	   in	   individual	   SI	   tumors	   and	   adjacent	   normal	   SI	   tissue	   taken	   from	  
individual	  VAK	  and	  VAKN	  mice,	  as	  indicated.	  	  Error	  bars	  represent	  SEM	  of	  technical	  triplicates.	  	  F)	  
Representative	   images	   of	   IHC	   analysis	   of	   nuclear	   beta-­‐Catenin	   and	   ERK	   phosphorylation	   in	  
tumours	   from	   VAK	   &	   VAKN	   mice.	   Scale	   bars	   =	   100µm	   (low	   res)	   &	   20µm	   (high	   res).	   G)	  
Representative	   images	   show	   ISH	   detection	   of	   Nuak1	   mRNA	   (red	   dots)	   in	   6	   randomly	   selected	  
tumors	  of	  VAKN	  mice,	  along	  with	  2	  from	  VAK	  controls.	  	  
	  























































































Figure	  S3:	  No	  effect	  of	  Nuak1	  deletion	  in	  otherwise	  wild-­‐type	  gut.	  	  Pertains	  to	  Figure	  2.	  
A)	   Representative	   images	   of	   small	   intestine	   from	  wild-­‐type	   (top	   panels)	   or	   homozygous	   floxed	  
Nuak1	  (lower	  panels)	  mice	  harvested	  6	  days	  after	  tamoxifen	  dependent	  activation	  of	  CreER	  in	  VN	  
mice,	   stained	   for	   histology	   (H&E);	   proliferation	   (BrdU);	   apoptosis	   (Cleaved	   Caspase	   3);	   and	  
differentiation	   (Lysozyme	  and	  PAS).	  N=3	   (Nuak1wt/wt)	   and	  3	   (Nuak1FL\FL).	   Scale	   bar	   =	   100µm.	   	  B)	  
Representative	  images	  of	  large	  intestine	  from	  mice	  as	  in	  (A).	  	  Scale	  bar	  =	  100µm.	  	  C)	  Quantification	  
of	  staining	  from	  (A	  &	  B).	  Black	  bars	  =	  Nuak1wt/wt;	  red	  bars	  =	  Nuak1FL\FL.	  	  	  Mean	  and	  SEM	  shown;	  ns	  
=	   not	   significant.	   	  D)	   Representative	   images	   of	   small	   intestine	   from	   from	  wild-­‐type	   (WT),	   Villin-­‐
CreERT2;Apcfl/fl;	   (VA)	   or	   Villin-­‐CreERT2;Apcfl/fl;Nuakfl/fl	   (VAN),	   stained	   for	   histology	   (H&E)	   and	  
proliferation	   (BrdU)	   N=3,	   Scale	   bar	   =	   100μM.	   	   E)	   Organoid	   cultures	   from	   wild-­‐type	   intestines	  
treated	  with	  vehicle	  (i)	  or	  2.5µM	  (ii);	  5µM	  (iii)	  or	  10µM	  (iv)	  Nuak1	  inhibitor	  HTH-­‐01-­‐015	  for	  48hrs.	  	  
























































































































































































































Port	  et	  al.	  
	  
Figure	  S4:	  Deletion	  of	  Nuak1	  suppresses	  NRF2-­‐dependent	  gene	  expression	  in	  MEFs.	  Pertains	  to	  
Figure	  3.	  
A)	  Schematic	  representation	  of	  selected	  NRF2-­‐dependent	  anti-­‐oxidant	  defense	  genes	  modulated	  
upon	  depletion	  of	  NUAK1.	   	  B)	  mRNA	  expression	  of	  selected	  NRF2	  target	  genes	   in	  Nuak1FL/FL	  (left	  
panel)	   and	   Nuak1WT/WT	   (right	   panel)	   MEFs	   after	   Adeno-­‐CRE	   infection.	   Data	   are	   presented	   as	  
percent	  of	  levels	  measured	  in	  uninfected	  controls.	  Mean	  and	  SEM	  of	  3	  independent	  experiments	  
are	   shown.	   Asterisks	   denote	   significance;	   ns	   =	   not	   significant	   (unpaired	   T-­‐test).	   C)	   Immunoblot	  
confirms	  deletion	  of	  Nuak1	  in	  Adeno-­‐CRE	  infected	  Nuak1FL/FL	  MEFs.	  	  D)	  4-­‐OHT	  inducible	  deletion	  of	  
Nuak1	   in	  Nuak1FL/FL	  MEFs	   stably	   infected	  with	  CreERT2-­‐expressing	   retrovirus.	   	  E)	  Apoptosis	   levels	  
measured	   in	   H2O2-­‐treated	   (500µM,	   48hrs)	  Nuak1FL/FL	  MEFs,	   with	   (OHT)	   and	   without	   (VC)	   CreER	  
mediated	  deletion	  of	  Nuak1.	  	  Similar	  results	  were	  observed	  after	  Adeno-­‐CRE	  mediated	  deletion	  of	  
Nuak1.	   	  Mean	  and	  SEM	  of	   technical	   triplicates	   from	  a	  representative	  experiment	  are	  shown.	   	  F)	  
Cumulative	   dead	   cell	   counts,	  measured	   by	   uptake	   of	   Sytox	   green	   reagent	   in	   cultures	   of	   SW480	  
(left)	   and	   SW620	   (right)	   cells,	   after	   treatment	   with	   HTH-­‐01-­‐015	   in	   the	   presence	   or	   absence	   of	  
Trolox	  (500µM).	  	  Results	  are	  representative	  of	  2	  experiments	  for	  each	  cell	  line.	  	  Error	  bars	  reflect	  
SD	  of	   technical	   triplicates.	  G)	   Rescue	  of	   small	   intestine	  derived	   spheroids	   from	  Nuak1	   inhibitor-­‐
induced	   death	   by	   exogenous	   anti-­‐oxidant	   Trolox,	   as	   per	   main	   Figure	   3L.	   	   Asterisks	   indicate	  
significance	   (2-­‐way	   ANOVA	   and	   Tukey’s	   post-­‐hoc	   test).	   H)	   Representative	   FACS	   detection	   of	  
cytosolic	   H2O2	   levels	   measured	   by	   CellRoxTM	   fluorescence	   after	   8hrs	   HTH-­‐01-­‐015	   (10µM)	  
treatment	   in	   the	   presence	   of	   Trolox	   (500µM).	   I)	  Mean	   (±SEM)	   CellRox	   fluorescence	   intensity	   in	  
SW480	   cells	   (technical	   triplicates)	   treated	   with	   HTH-­‐01-­‐015	   and/or	   Trolox	   as	   per	   (H).	  
Representative	  of	  2	  independent	  experiments.	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Figure	  S5:	  Regulation	  of	  NRF2	  by	  NUAK1	  is	  indirect.	  	  Pertains	  to	  Figure	  5.	  
A)	   Anti-­‐Phospho-­‐pan-­‐AMPK-­‐substrate	   immunoblot	   of	  whole	   cell	   extracts	   (left	   4	   lanes)	   and	   anti-­‐
FLAG	   immunoprecipitates	   (right	  4	   lanes)	   from	  U2OS	  cells	   transfected	  with	  FLAG-­‐tagged	  NRF2	  or	  
empty	  vector	  (ev),	  as	  indicated.	  	  B)	  In	  vitro	  kinase	  activity	  of	  commercially	  purified	  NUAK1	  towards	  
a	  NRF2	  peptide	  containing	  a	  putative	  AMPK	  consensus	  motif.	  	  CDC25C	  peptide	  serves	  as	  positive	  
control.	   	  Error	  bars	   reflect	   technical	   triplicates.	   	  C)	  NRF2	   immunoblot	  upon	  Cyclohexamide	   (chx)	  
treatment	  of	  SW480	  cells	   for	   the	   indicated	   times	  with	  and	  without	  depletion	  of	  NUAK1.	   	   Lower	  
panels	  show	  Image	  J	  quantification	  of	  NRF2	  protein	  from	  the	  blot	  presented	  D)	  NRF2	  immunoblots	  
in	  cytosolic	  (CE)	  and	  nuclear	  (NE)	  extracts	  of	  CRC	  cell	   lines	  treated	  with/without	  500µM	  H2O2	  for	  
30	  minutes.	   Lamin	  A/C	  and	  Tubulin	   immunoblots	   indicate	  purity	  of	   sub-­‐cellular	   fractionation.	  E)	  
Depletion	  of	  NUAK2	  suppresses	  peroxide-­‐induced	  nuclear	  accumulation	  of	  NRF2	   in	  SW620	  cells.	  
Immunoblot	  (right	  panel)	  confirms	  selective	  depletion	  of	  NUAK2	  by	  siRNA.	  F)	  Schematic	  of	  SILAC	  
based	   phospho-­‐proteomic	   analysis	   of	   U2OS	   cells	   after	   treatment	   with	   HTH-­‐01-­‐015.	   G)	   NRF2	  
immunoblot	   of	   NUAK1	   depleted	   SW480	   cells,	   treated	   with	   and	   without	   GSK3β	   inhibitor	  
(CHIR99021,	   3µM	   for	   6hrs),	   followed	   by	   cyclohexamide	   (100pg/ml)	   for	   the	   indicated	   durations.	  	  
Note	  that	  the	  NUAK1-­‐depleted	  lanes	  without	  GSK3βi	  treatment	  are	  the	  same	  shown	  in	  panel	  (B).	  
Lower	  panel	  shows	  quantification	  as	  per	  (B).	  	  H)	  Depletion	  of	  PTEN	  rescues	  nuclear	  accumulation	  
of	  NRF2	  in	  NUAK1	  depleted	  SW480	  cells.	  Blots	  are	  representative	  of	  2	  independent	  experiments.	  































































































































































































Figure	  S6:	  NAC	  has	  no	  effect	  on	  NUAK1-­‐replete	  colorectal	  tumors.	  	  Pertains	  to	  Figure	  7.	  
A)	  Nuak1/2	  immunoblots	  upon	  treatment	  of	  MEFs	  carrying	  either	  of	  the	  shNuak1-­‐612	  or	  shNuak1-­‐
1533	   alleles	   or	   control	   MEFs	   (WT)	   with	   1µg/ml	   doxycycline	   for	   72hrs.	   	   B)	   Schematic	   of	   the	  
experimental	  setup	  for	  main	  Figure	  7	  and	  below:	  (1)	  Transient	  activation	  of	  CreER	  by	  Tamoxifen	  
injection	  deletes	  the	  floxed	  Apc	  allele	  and	  initiates	  gut-­‐restricted	  expression	  of	  rtTA3.	  (2)	  Mice	  are	  
administered	   dextran	   sodium	   sulfate	   (DSS)	   for	   5	   days	   to	   drive	   accelerated	   turnover	   of	   colonic	  
epithelium,	  leading	  to	  sporadic	  loss	  of	  the	  remaining	  wild-­‐type	  Apc	  allele	  (3)	  and	  tumour	  initiation.	  
64	   days	   after	   Tamoxifen	   injection,	  mice	  were	   administered	   doxycycline	   to	   induce	   expression	   of	  
shRNA	  targeting	  Nuak1	  (4).	  	  Mice	  were	  harvested	  for	  examination	  after	  1	  week	  of	  Nuak1	  depletion	  
(day	  70	  post-­‐induction).	  C)	  RNA-­‐Scope	  ISH	  shows	  continued	  expression	  of	  Nuak1	  mRNA	  in	  tumors	  
that	  were	  harvested	  from	  the	  doxycycline-­‐induced	  shNuak-­‐612-­‐expressing	  VA	  mouse	  encircled	  in	  
Fig.	  6A	  (panel	  iii),	  and	  a	  residual	  tumor	  from	  an	  shNuak-­‐1533-­‐expressing	  mouse	  (panel	  iv).	  	  Panels	  i	  
&	  ii	  show	  adjacent	  normal	  tissue	  from	  the	  same	  gut	  shown	  in	  iii.	  	  Arrowheads	  point	  to	  examples	  of	  
specific	   signal.	   	   Scale	   bars	   =	   50	  µm	   (panels	   i,	   iii	   &	   iv)	   and	   30	  µm	   (panel	   ii).	   	   Panels	   v-­‐viii	   show	  
variable	   levels	   of	   continued	  NUAK1	   expression	   in	   additional	   tumors	   that	   persist	   after	   7	   days	   of	  
RNAi	  induction	  (ie.	  “escapers”	  from	  effective	  RNAi).	  	  D)	  Licor	  ROSStarTM	  ex	  vivo	  detection	  of	  ROS	  in	  
colonic	  tumors	  induced	  to	  express	  shNUAK1-­‐1533	  for	  2	  days,	  compared	  with	  un-­‐induced	  controls.	  
E)	   RNA-­‐SEQ	   measurement	   of	   selected	   NRF2	   target	   genes	   in	   tumors	   (N=6)	   from	   mock-­‐treated	  
control	   mice	   (black	   bars)	   compared	   with	   shNuak1-­‐1533	   expressing	   tumors	   (N=6,	   red	   bars),	  
harvested	  after	  2	  days	  of	  shRNA	  induction.	  Data	  are	  normalized	  to	  the	  Mean	  expression	  of	  control	  
tumors.	  	  Mean	  and	  SEM	  shown.	  F)	  Whole-­‐mount	  examples	  of	  large	  intestines	  from	  experimental	  
mice,	  expressing	  shNUAK1-­‐1533	  for	  1	  week	  where	   indicated,	   in	  the	  presence	  or	  absence	  of	  NAC	  
anti-­‐oxidant	  supplementation.	  Arrowheads	  point	  to	  individual	  tumors,	  the	  dashed	  line	  indicates	  a	  
continuous	  string	  of	  tumors.	  G)	  NAC	  has	  no	  effect	  on	  the	  number	  of	  tumors	  per	  mouse,	  the	  total	  
tumor	  burden,	  or	  the	  size	  of	  individual	  tumors	  in	  Nuak1-­‐replete	  mice.	  	  Graphs	  depict	  Mean	  (blue	  
bars)	  and	  SEM	  (red	  bars)	  of	  the	  indicated	  parameters	  in	  mice	  treated	  (N=3)	  or	  not	  (N=7)	  with	  NAC.	  	  
Note	  that	  the	  data	  from	  untreated	  mice	  (nt)	  are	  the	  same	  as	  in	  main	  figure	  6A	  (-­‐).	  	  No	  parameter	  























































1. Cell cycle_Influence of Ras & Rho proteins on G1/S transition
2. Neurogenesis_NGF/TrkA MAPK-mediated signaling
3. Transcription_Hif-1 targets
4. Cell adhesion_Chemokines & adhesion
5. IGF family signaling in colorectal cancer
6. Oxidastive phosphorylation
7. Apoptosis and survival_NGF/TrkA PI3K-mediated signaling
8. Signal transduction_PTEN pathway
9. Cytoskeletal remodeling_Regulation of actin cytoskelton
organization by the kinase effectors of Rho GTPases
10. Development_IGF-1 receptor signaling
11. Aberrant B-Raf signaling in melanoma progression
12. Cell adhesion_Integrin-mediated cell adhesion & migration
13. Signal transduction_mTORC2 downstream signaling
15. HBV signaling via protein kinases leading to HCC
14. Ligand-independent activation of Andrigen receptor in prostate cancer
16. Ovarian cancer (main signaling cascades)
17. Development_WNT signaling pathway Part. 2
18.Stellate cells activation and liver fibrosis 
19. Apoptosis & survival_BAD phosphorylation
20. Neurophysiological process_Receptor-mediated axon growth repulsion
21. Transcription_Androgen Receptor nucelar signaling
22. IL-6 signaling in multiple myeloma
23. Cytoskeletal remodeling_Integrin outside-in signaling
24. Normal & pathological TGF-beta-mediated regulation of cell proliferation
26. Signal transduction_AKT signaling
25. Immune response_IL-4 signaling pathway
27. Signal transduction_mTORC1 downstream signaling
28. Development_EGFR signaling pathway
29. Cell cycle_Regulation of G1/S transtion (Part 1)
30. Androgen receptor activation and downstream signaling in Prostate cancer
31. Development_Regulation of cytoskeletal proteins in oligodendrocyte
differentiation & myelination
32. Immune response_IL-3 signaling via ERK and PI3K
33. Main growth factor signaling cascaeds in multiple myeloma cells
34. Cell cycle_Start of DNA replication in early S phase
35. Development_TGF-beta-dependent induction of EMT via RhoA, PI3K & ILK
36. Development_Thrombopoietin-regulated cell processes
37. Translation_Regulation of EIF2 activity
38.Translation_Regulation of EIF4 activity 
39. Immune response_IFN-alpha/beta signaling via PI3K & NF-ΚB pathways
40. Development_Growth factors in regulation of oligodendrocyte precursor cell proliferation
41. NRF2 regulation in oxidative stress response
42. Immune response_M-CSF-receptor signaling pathways
43. Development_TGF-beta receptor signaling
44. Development_Adenosine A2A receptor signlaing
45. Cytoskeletal remodeling_Regulation of actin cytoskeleton nucleation & polymerisation
 by Rho GTPases
46. Apoptosis & survival_Granzyme B signaling
47. Tau pathology in Alzheimer disease
48. Cell adhesion_Histamine H1 receptor signaling in the interruption
of cell barrier integrity
49. Regualiton of lipid metabolism_Insulin signalin: generic cascades
50. Development_PIP3 signaling  in cardiac myocytes
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Table	  S1:	  Analysis	  of	  biological	  pathways	  modulated	  by	  depletion	  of	  either	  NRF2	  or	  NUAK1	  in	  
SW480	  cells.	  	  Metacore	  GeneGO	  analysis	  shows	  the	  pathways	  most	  significantly	  regulated	  (up	  or	  
down)	  upon	  depletion	  of	  NRF2	  (blue	  bars)	  or	  NUAK1	  (orange	  bars),	  ranked	  by	  p-­‐value	  (-­‐log).	  


















































































Cell cycle_Start of DNA replication in early S phase
Apopotosis & survival_Role of PKR in stress-induced apoptosis
GTP-XTP metabolism
CTP/UTP metabolism
DNA damage_ATM/ATR regualtion of G1/S checkpoint
Cell cycle_Role of APC in cell cycle
Apoptosis & survival_Role of HTR1A signaling
Transcription_HIF-1 targets
Immune response_Role of PKR in stress-induced antiviral cell repsonse
Cell cycle_Influence of Ras & Rho proteins on G1/S transition
Transport_RAN regluation pathway
NRF2 regulation of oxidative stress response
Development_Regulaiton of telomere length & cellular immortalization
Ovarian cancer (main signaling cascades)
DNA damage_NHEJ mechanims of DSBs repair
CFTR folding & maturation (normal & CF)
Immune response_B cell antigen receptor (BCR) pathway
Oxidative stress_ROS-mediated activation of MAPK via inhibition of phosphatases
DNA damage_Role of BRCA1 & BRCA2 in DNA repair
Neurogenesis_NGF/TrkA MAPK-mediated signaling
Aberrant B-Raf signaling in melanoma progression
Development_PDGF signaling via STATs and NF-ΚB
Transcription_Sirtuin6 regulation & function
Development_Positive regulation of STK3/4 (Hippo) pathway &
negative regulation of YAP/TAZ function
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Table	  S2:	  Analysis	  of	  most	  significantly	  down-­‐regulated	  biological	  pathways	  after	  depletion	  of	  
either	  NRF2	  or	  NUAK1	  in	  SW480	  cells.	  	  Metacore	  GeneGO	  analysis	  shows	  the	  pathways	  most	  
significantly	  down-­‐regulated	  upon	  depletion	  of	  NRF2	  (blue	  bars)	  or	  NUAK1	  (orange	  bars),	  ranked	  
by	  p-­‐value	  (-­‐log).	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Table	  S3:	  NUAK1	  inhibition	  suppresses	  inhibitory	  phosphorylation	  of	  GSK3β  
Quantitative	  changes	  in	  phosphorylation	  of	  selected	  proteins	  after	  1hr	  treatment	  of	  U2OS	  cells	  
with	  10µM	  HTH-­‐01-­‐015.	  	  GSK3	  substrate	  motifs	  were	  identified	  by	  Perseus	  and/or	  Phosphosite	  
Plus	  and	  verified	  where	  indicated	  (X)	  using	  the	  Princeton	  &	  KEA	  phospho-­‐proteomic	  databases.	  
